>> MEETING OF THE NATIONAL
LIBRARY BOARD OF REGENTS TO
ORDER.
I WOULD LIKE TO START BY
WELCOMING THE BOARD MEMBERS, NLM
STAFF, THOSE ON THE VIDEOCAST,
THIS MEETING IS NOW BEING
RECORDED AND BROADCAST LIVE ON
NIH VIDEOCAST.
TODAY'S JULY 8th MEETING TAKES
THE PLACE OF THE BOARD OF
REGENTS WINTER MEETING WHICH WAS
CANCELED FOR ITS ORIGINALLY
SCHEDULED DATE OF FEBRUARY 11,
2025.
WE WILL START WITH RECOGNITION
OF THE BOARD MEMBERS AND
EXOFICIO MEMBERS AND I WOULD
LIKE TO TAKE A MOMENT TO
RECOGNIZE THE BOARD OF REEJ ENDS
MEMBERS AND WE -- REEK END
MEMBERS AND WE WOULD LIKE TO
THANK YOU FOR YOUR PREVIOUS
SUPPORT.
AS MENTIONED PREVIOUSLY WHEN
YOU'RE NAME IS,A NOUNSED PLEASE
TURN YOUR VIDEO AND GIVE A BRIEF
INTRODUCTION OF YOURSELF.
SO I WILL START WITH DR. JIM
SOMINO,.
>> JIM, PROFESSOR OF BIOFARMICAL
AND DATA SCIENCE AT UNIVERSITY
OF ALABAMA BIRMINGHAM.
>> DR. CHRIS FOREST?
>> HI, CHRIS FOREST, PHYSICIAN
AT THE CHILDREN'S HOSPITAL OF
PHILADELPHIA, AND THE UNIVERSITY
OF PENNSYLVANIA.
I ALSO LEAD A NATIONAL NETWORK
OF CHILDREN'S HOSPITALS CALLS
PEDSNET.
>> DR. MITCH KATZ.
>> YOU'RE MUTED.
>> MITCH, YOU'RE ON MUTE.
>> SORRY ABOUT THAT, HI, I'M
DR. MITCH KATZ, I'M A PRIMARY
CARE DOCTOR AND CEO OF NEW YORK
CITY HEALTH AND HOSPITALS.
>> THANK YOU DR. ANN QUIDICK,
I'M PROFESSOR OF MEDICAL
PHYSIOLOGY AT UNIVERSITY OF
WISCONSIN AND I LEAD THE RAT
GENOME DATABASE.
>> DR. LORE,.
>> HI, EVERYONE I'M DR. LORE,
WISCONSIN SCHOOL OF MEDICINE
NURSING AND I DO WORK ON HEALTH
INFORMATICS OR HEALTH
VISUALIZATION, THANK YOU.
>> RASMUS NEILSEN.
>> HI, I'M RASMUS NEILSEN
COMPUTATION BIOLOGIST AND
INTEGRATE I REALLY BIOLOGIST AT
UC BERKELEY.
>> CHRIS SHAFFER,.
>> CHRIS SHAFFER, UNIVERSITY
LIBRARIAN, ADJUNCT PROFESSOR AT
THE UNIVERSITY OF CALIFORNIA
SAN FRANCISCO.
FILIB WALKER, PHILLIP WALKER,
DIRECTOR OF THE BIOMEDICAL
LIBRARY OF VANDERBILT
UNIVERSITY, ALSO ADJUNCT FACULTY
AND INFORMATICS TRACK WITH THE
VANDERBILT SCHOOL OF NURSING.
>> AND FOR EXOFICIO PRESENT
MICHELLE ELOKONICH.
>> I AM THE DEPUTY DIVISION
DIRECTOR OF EPITHELIAL GREATIVE
ORGANISMAL SYSTEMS AND
BIOLOGICAL DIRECTOR AT THE
NATIONAL SCIENCES FOUNDATION.
>> REAR ADMIRAL DENISE HINTON.
>> GOOD MORNING, REAR ADMIRAL
DENISE HINTON, DEPUTY SURGEON
GENERAL, REPRESENTING THE OFFICE
OF THE SURGEON GENERAL UNTIL THE
NEW SURGEON GENERAL GETS
APPOINTED.
PLEASURE TO BE WITH YOU THIS
AFTERNOON.
THANK YOU.
>> THANK YOU.
TWO WELCOMING 2 NEW
EXPECTATIONS-OFICIO MEMBERS,
DR. CHADRY, REPRESENTS LIBRARY
OF CONGRESS WHERE HE SERVES AS
DIRECT ASSISTANT DIRECTOR OF
DOMESTIC POLICY DIVISION
DR. WALTER REPRESENTS THE ARMY
MEDICAL EDUCATION DIRECTOR
WITHIN THE OFFICE OF THE SURGEON
GENERAL.
GOOD TO HAVE YOU BOTH.
>> THANK YOU.
>> SO THANK YOU AGAIN TO ALL
BOARD OF REGENTS MEMBERS AND
EXOAPPROXIMATE FICIO MEMBERS, WE
HAVE A QUORUM PRESENT AND WE
WILL PROCEED WITH TODAY'S,
AGENDA AND WE WILL START WITH
THE MEETING, MINUTES AND FUTURE
MEETINGS.
SO THE FUTURE BOARD OF REGENTS
MEETING, THE 2025 FALL MEETING
AS WE'VE DISCUSSED IN GOING TO
BE IN OCTOBER AND NOT SEPTEMBER,
SO IT'S OCTOBER 27th, TO 28,
2025.
IT'S BEEN CONFIRMED AND IT'S AN
IN-PERSON MEETING.
THE 2026 BOARD OF REGENTS WINTER
MEETING UPON BE ON
FEBRUARY 10th 2026 AND THAT
WILL BE A VIRTUAL MEETING, THE
2026 BOARD OF REEJ ENDS SPRING
MEETING WILL BE MAY 26th, AND
THAT'S VIRTUAL AND THE 2026 FALL
MEETING WILL GO BACK TO
SEPTEMBER, BE
SEPTEMBER 15-162026 IN-PERSON
AND THAT'S ALSO CONFIRMED.
SO, FUTURE PROPOSED MEETING WILL
BE THE 2027 BOARD OF REGENTS
WINTER MEETING, PROPOSED DATE IS
FEBRUARY 9th, 2027, AND THE
SPRING MEDING PROPOSED DATE IS
MAY 11th, 2027.
SO ARE THERE ANY QUESTIONS OR
CONCERNS ABOUT THE MEETING DATES
FOR THE BOARD OF REGENTS?
OKAY, AND THEN, FUTURE MEETING
DATES FOR THE MLA, MAY 19-2022,
OF 2026 IN MILWAUKEE WISCONSIN,
THE AAMC MEETING WILL BE
NOVEMBER 1-5 OF 2025 IN SAN
ANTONIO TEXAS AND THE FALL
MEETING THIS YEAR IS
NOVEMBER 15-19 IN ATLANTA,
GEORGIA.
SO IF THERE ARE NO QUESTIONS OR
CONCERNS ABOUT ANY OF THE
MEETING DATES WE CAN MOVE TO
APPROVAL OF THE MAY EIGHTH
MEETING MINUTES.
WE ALL RECEIVED COPIES OF THE
MINUTES SO I ASSUME WE'VE HAD A
CHANCE TO LOOK OVER THEM SO DO
WE HAVE ANY -- IF WE DON'T HAVE
ANY QUESTIONS ABOUT THE MEETING
MINUTES, I WOULD NEED SOMEONE TO
MOVE OR SECOND FOR APPROVING THE
MEETING MINUTES.
>> MOVE TO APPROVE.
>> DO WE HAVE A SECOND?
>> SECOND.
>> ALL IN FAVOR, RAISE YOUR HAND
AND A AYE.
>> OKAY, SO WE HAVE THE MAIN
MEETING MINUTES APPROVED.
>> NEXT, WE WILL HAVE THE REPORT
FOR ACTING NLM DIRECTOR
DR. STEVE SHERRY AND I WILL TURN
THE FLOOR TO HIM NOW.
>> IT WAS A GREAT MEETING THEN,
AND NEXT SLIDE PLEASE, SINCE
WE'VE COVERED SO MUCH AT THAT
MEETING MAY, I ONLY HAVE A
COUPLE BRIEF UPDATES TODAY
INCLUDINGOT BUDGET.
NEXT SLIDE, PLEASE.
AS WE NOTED LAST MONTH, NIH IS
CURRENTLY UNDER A CONTINUING
RESOLUTION AND THAT WILL
CONTINUE TO THIS SEPTEMBER 2025,
UNDER THE CONTINUING RESOLUTION,
NLM REMAINS APPROPRIATED AT THE
FY2024 APPROPRIATION LEVEL.
THE NIH AND THE NLM BUDGET FOR
FISCAL YEAR 2026 IS STILL
UNKNOWN.
THE PRESIDENT AS SUBMITTED HIS
PROPOSED BUDGET, THE FISCAL YEAR
2026, WHICH WILL BE A 40%
REDUCTION OF THE FISCAL YEAR
2025, AND IT WILL FUND NIH AT
$365 MILLION.
-- MLM AT $365 MILLION.
NIH'S BUDGET WILL BE
APPROPRIATED BY CONGRESS AND AT
THIS TIME, CONGRESS HAS NOT
FINALIZED FUNDING FOR NIH.
WE DON'T HAVE THE NUMBERS YET.
NEXT SLIDE, PLEASE.
MOVING ON, I WOULD LIKE TO SHARE
WITH YOU, A NEW NLM VIDEO THAT
HIGHLIGHTS A PROJECT FUNDED BY
NLM EXTRAMURAL PROGRAM, MUCH OF
OUR DOCTORS WORK NOW DAYS IS
DOCUMENTS PATIENT ISHT ACTIONS
WHICH TAKES TIME AWAY FROM
PATIENTS AND CAN QUICKLY LEAD TO
BURN OUT, AFTER ALL WHAT DOCTOR
GOT INTO HEALTHCARE JUST TO FILL
OUT FORMS.
DR. KEVIN JOHNSON IS AN NLM
FUNDED INVESTIGATOR FROM THE
UNIVERSITY OF PENNSYLVANIA AND
HE LOOKED AT THE STATISTICS AND
FOUND THAT FOR EVERY HOUR OF
PATIENT FACE TIME PHYSICIANS
SPEND AT LEAST 2 HOURS
DOCUMENTING THAT ENCOUNTER.
SO WE ASKED WHAT IF AI COULD
GENERATE DOCUMENTATION FOR THEM
INSTEAD.
SO LET'S LOOK AT THE VIDEO AND
SEE WHAT HE LEARNED.
[♪ MUSIC ♪]
>> AS A PEDIATRICIAN AS A
PHYSICIAN, THE BIGGEST CHALLENGE
WE FACE RIGHT NOW HAS TO DO WITH
BURN OUT.
>> CLINICIAN BURN OUT IS AN
ONGOING CHALLENGE AND I THINK
CERTAINLY, DOCUMENTATION IS PART
OF THAT.
A LOT OF OUR JOB IS
DOCUMENTATION IN 1 WAY OR
ANOTHER.
>> THERE HAVE BEEN A LOT OF
TECHNOLOGIES USE INDEED
HEALTHCARE BUT ALMOST NEVER IN
THE EXAM ROOM BECAUSE IT'S SO
HARD TO GET ACCESS TO THE DATA
YOU WOULD USE TO TRAIN VISUAL
LANGUAGE MODELS.
SO THE PROJECT WE CALLED REDUCE,
WHICH ESSENTIALLY STAND FIST ARE
REIMAGINING DOCUMENTATION USING
COMPUATIONAL ENHANCEMENT, THE
GOAL OF THAT PROJECT IS TO THINK
NOT JUST THOUGH ABOUT
DOCUMENTATION BUT TO GET BEYOND
IT AND TO THINK ABOUT WAYS IN
WHICH THE ENTIRE VISIT CAN BE
QUANTIFIED, DOCUMENTED, AND
REUSED IN SUPPORT OF PATIENT
CARE AND QUALITY.
>> I AM A PARTICIPANT IN
DR. JOHNSON'S TRIAL.
I AM SORT OF OUTFITTED WITH SOME
TECHNOLOGIES, SO, A CAMERA THAT
GOES OVER MY HEAD, THAT RECORDS,
MY INTERACTION WITH THE PATIENT
AND THEN THERE'S A CAMERA
RECORDS THE WHOLE ROOM AND THE
SCREEN AND WE GO THROUGH THE
REGULAR MEDICAL PROBLEMS, ET
CETERA FROM START TO FINISH.
>> ONE OF THE MOST EXCITING
PARTS OF THE PROJECT THAT THE
PIONEER AWARD WAS ABLE TO ALLOW
US TO DO WAS TO SPEND THE FIRST
YEAR IN A GOAL-FREE STATE,
REALLY INVESTIGATORRING WHAT
HAPPENS IN PRIMARY CARE, SO
WE'VE BEEN WATCHING SIMULATIONS
AND PATIENT CARE FOR ABOUT A
YEAR NOW.
WE HAVE A GROUP CALLED THE BOOK
CLUB, AND THE NAME SEEMS ODD
UNTIL YOU THINK ABOUT THE GOAL
OF A BOOK CLUB.
IN OUR CASE WE ARE USING THE
VIDEOS THAT WE'RE RECORDING AS
PART OF THE REDUCE PROJECT TO
SUBSTANTIATE CONVERSATIONS IN
THE BOOK CLUB.
>> ONE OF THE THINGS THAT AMAZED
ME IS THEY SPENT LITERALLY ABOUT
6 MINUTES DOING PAPERWORK AND
NEXT APPOINTMENTS AND REFERRALS.
SIX MINUTES, I MEAN YOU DIDN'T
GO TO MEDICAL SCHOOL TO FIGURE
OUT A CALENDAR.
>> AND WE NOTICED WHEN WE WERE
WATCHING THESE VIDEOS THAT IT IS
ABSOLUTELY THE CASE THAT DOCTORS
AREN'T DOCTORING ANYMORE AND
EVERYTHING THAT WE'RE THINKING
ABOUT RIGHT NOW HAS TO DO WITH
HOW DO WE AUTOMATE SOMETHING,
HOW DO WE PROVIDE SOMETHING
WITHOUT ASKING ANYTHING ELSE OF
EITHER THE PATIENT OR THE
CLINICIAN OTHER THAN JUST HAVE
THE VISIT YOU NEED TO HAVE
TODAY.
>> YOU KNOW I THINK
FUNDAMENTALLY WHY MOST OF US GO
INTO MEDICINE, WHAT DRIVES
PHYSICIANS, IS THE
PATIENT-DOCTOR RELATIONSHIP.
ANYTHING THAT WILL HELP
FACILITATE THAT RELATIONSHIP IS
VALUABLE AND I KNOWLEDGE THERE
IS A LOT OF LEVERAGE TO MAKE
THIS DATA MORE EFFICIENT.
SO MY HOPE IS THAT THIS PROJECT
BEGINS A MOVEMENT OF PEOPLE
THINKING ABOUT HOW WE SHOULD BE
REIMAGINING THE HELT
CARE-PATIENT INTERACTION, USING
VIDEOS FROM THESE SITES AROUND
THE COUNTRY AND USING THAT TO
CREATE AND INNOVATE IN SPACES
WE'VE NEVER THOUGHT ABOUT.
>> ALL RIGHT, THANK YOU.
WE'RE LOOKING FORWARD TO MORE
ABOUT HOW PROJECTS LIKE THIS CAN
REIMAGINE THE RELATIONSHIP
BETWEEN PATIENTS AND PHYSICIANS
AND CAN GIVE US 6 MINUTES OF
INVALUABLE TIME WITH OUR CARE
PROVIDERS, THAT WOULD BE
EXCITING.
ALL RIGHT, MOVING ON.
YOU MAY HAVE SEEN A SLIDE BEFORE
AND MAY HAVE HEARD ME SAY, THAT
NLM'S SUCCESS IS DRIVEN BY THE
MEMBERS OF OUR SENIOR LEADERSHIP
TEAM, I HAVE THEM HERE IN THE
ROOM WITH ME NOW, I WOULD LIKE
TO SHARE AGAIN MY APPRECIATION
FOR THIS TEAM OF LEADERS FOR
THEIR RESILIENCE AND SUPPORT OF
ME AS THE ACTING DIRECTOR OF NLM
AND EVERYTHING THEY'RE DOING FOR
NLM SO THANK YOU ALL.
I ALSO WANT TO AGAIN RECOGNIZE
ALL NLM STAFF FOR WHAT THEY HAVE
DONE AND CONTINUE TO DO TO
FOSTER 1 NLM AND SUPPORT THE
MISSIONS OF NLM AND NIH OVER
ALL.
NEXT SLIDE, PLEASE.
I'M GRATEFUL FOR YOUR SERVICE TO
ADVANCE THE HEALTH OF OUR
COMMUNITIES AND TO APPRECIATE
ALL YOU HAVE CONTRIBUTED TO THE
NLM JOURNEY.
WE A FANTASTIC STAFF HERE AND
THEY'VE BEEN INCREDIBLE LOAMACYY
RESILIENT THIS YEAR SO AGAIN,
JUST MY GRATITUDE AND THANKS TO
ALL OF THEM.
NEXT SLIDE, PLEASE.
I WOULD NOW LIKE TO TURN IT OVER
TO OUR ASSISTANT DIRECTOR FOR
POLICY DREPMENT, FOR AN UPDATE
ON POLICY AND LEGISLATION
ACTIVITIES OF INTEREST ON THE
NLM.
NTHANK YOU, AND GOOD MORNING
EVERYONE, THIS MORNING I WILL
OFFER SOME BRIEF RECENT POLICY
AND LEGISLATIVE UPDATES,
SOPHISTER A REMINDER A WEEK AGO
TODAY, THE 2024 NIH PUBLIC
ACCESS POLICY WENT INTO EFFECT,
TO MAKE NIH RESEARCH FUNDING
REALLY QUICKLY AVAILABLE TO THE
PUBLIC.
THERE'S ALSO BEEN RECENT
ACTIVITY IN ARTIFICIAL AND
INTELLIGENCE OR AI, IN
PARTICULAR, SINCE THE LAST BOARD
OF REEJENTS MEETING IN MAY, NIH
RELEASED 2 REQUESTS FOR
INFORMATION ON AI, 1 ON
JUNE 3rd THAT FOCUSED ON --
FOCUSES ON INFORMING THE
DEVELOPMENT OF AN NIH AI
STRATEGIC PLAN AND A 1 YEAR
ACTION PLAN.
PREVIOUSLY AT THE END OF MAY,
ANOTHER REQUEST FOR INFORMATION
WAS RELEASED TO SEEK PUBLIC
INPUT ON POTENTIAL STRATEGIES TO
MITIGATE HUMAN GENOMIC DATA
LEAKAGE WHEN DEVELOPING
GENERATIVE AI, TOOLS AND
APPLICATIONS.
BOTH OF THOSE ARE STILL OPEN FOR
PUBLIC COMMENT THROUGH MIDJULY.
AND PREVIOUSLY, AND MIDMAY, THE
NATIONAL ACADEMY OF MEDICINE
ANNOUNCED THE RELEASE OF A CODE
OF CONDUCT FOR THE RESPONSIBLE
AND EFFECTIVE USE OF AI AND IN
HEALTH AND MEDICINE.
OT LEGISLATIVE SIDE AS STEVE
NOTED THE FISCAL YEAR 2026 NIH
BUDGET JUSTIFICATION WAS RELEASE
OFFICE OF DIVERSITY JUNE 6th,
FOLLOWING THE RELEASE OF THE
DEPARTMENT OF BUDGET IN BRIEF.
THE JUSTICE BOJ E BUJ THE
CONSOLIDATION OF NLM, THE
NATIONAL GENOME HUMAN GENOME
INSTITUTE, NATION AT INSTITUTE
OF BIOEMERGENCYING AND
BIOIMANNUALING AND ALSO INTO THE
NIGMS, AND SO FOR THAT REASON,
NLM PROGRAMS ARE INCLUDED IN THE
NIGMS CONGRESSIONAL
JUSTIFICATION WHICH WAS ALSO
RELEASED IN JUNE.
>> THERE HAVE BEEN 2
CONGRESSIONAL HEARINGSOT
PRESIDENT'S BUDGET REQUEST FOR
BOTH OF THE DEPARTMENT AND NIH,
ABOUT A MONTH AGO ISSUES THE NIH
DIRECTOR TESTIFIED BEFORE THE
SENATE APPROPRIATION
SUBCOMMITTEE ON LABOR, HUMAN
SERVICES AND HEALTH RELATED
AGENCY AND MOST RECENTLY ON
JUNE 24th, THE SECRETARY
TESTIFIED BEFORE THE HOUSE
ENERGY AND COMMERCE HEALTH
SUBCOMMITTEE.
AS A REMINDER AND STEVE
MENTIONED THESE HEARING PROVIDE
CAB NITRIC OXIDE MEMBERS AND
AGENCY LEADERS TO DEFEND FUNDING
NEEDS AS PART OF THE ANNUAL
APPROPRIATION PROCESS WHICH IS
JUST GETTING UNDERWAY FOLLOWING
HEARINGS, DIFFERENT
SUBCOMMITTEES WILL HAVE TO DRAFT
AND REFINE BILLS, THOSE NEED TO
BE VOTED OUT OF SUBCOMMITTEES
AND THEN COMMITTEES AND BROUGHT
TO EACH CHAMBER FOR AMENDMENTS
AND DEBATES AND EVENTUALLY,
HOUSE AND SENATE VERSIONS HAVE
TO BE RECONCILED AND ONCE ALL
RESOLVED ALL FINAL BILLS RETURN
TO THE CHAMBER FOR A VOTE BEFORE
GOING TO THE PRESIDENT FOR
SIGNATURE.
OTHER BRIEF UPDATES, 5 BILLS OF
TOPICS OF THE INTEREST TO NIH
AND NLM HAVE BEEN INTRODUCED
SINCE THE LAST BOARD OF REGENTS
MEETING RANGING ON TOPICS SUCH
AS SAFETY AND SECURITY OF
BIOLOGICAL RESEARCH, AI TEST
BEDS AND TRAINING AND NIH
RESEARCH PROGRAMS, AND THEN
FINALLY, I WILL LIKE TO MENTION
A COUPLE OF UPDATES ON KEY
DEPARTMENT APPOINTMENTS,
GIMO'NEIL WAS SWORN IN AS DEPUTY
SECRETARY OF THE DEPARTMENT
EARLY LAST MONTH IN THE SENATE
COMMITTEE ON HEALTH LABOR AND
CONFIRMATIONS HELD A
CONFIRMATION MEETING ON THE
NOMINATION FOR SUSAN WHYERS TO
BE THE DIRECTOR IN LATE JUNE.
WITH THAT I WILL TURN IT OVER TO
STEVE.
>> THANK YOU THERESA, WITH THAT
UPDATE WE NEW CONCLUDE THE
DIRECTOR'S PRESENTATION AND I I
WILL TURN THE FLOOR OVER TO YOU
LOLA FOR QUESTIONS AND
PRESENTATIONS.
>> THANK YOU SO MUCH SO WE WILL
OPEN THE FLOWER FOR GENERAL
DISCUSSION BECAUSE I'M SURE
PEOPLE HAVE QUESTIONS.
I DO HAVE A QUESTION ABOUT THE
POTENTIAL IMPACT OF THE BUDGET,
BUT I'LL LET OTHERS GO FIRST.
ANY QUESTIONS FROM BOARD
MEMBERS?
>> I WILL ASK A QUESTION, HOW
DISCIPLINARY FINNIVE IS THIS
COLLAPSING OF THE 27 INSTITUTES
INTO 8?
>> I WILL SAY I DON'T KNOW THAT
DEFINITIVE IS THE RIGHT WORD.
I THINK WE'RE STARTING A
LEGISLATIVE PROCESS, THAT
SUGGESTS THE OUTLINE FOR THE
SUBCOMMITTEE, HEARINGS
TESTIMONY, STAKEHOLDERS,
CERTAINLY OPINIONS AROUND THIS
SO I THINK WE HAVE JUST HAVE TO
SEE, WHAT THE PROCESS WILL
REVEAL AROUND INTENTIONS AND JAY
BHATTACHARYA SAID IN HIS
TESTIMONY WHAT WORKS BEST FOR
RESEARCH AND ACCOMPLISHING OUR
MISSION AND THAT'S WHAT HE'S
REALLY CENTERED ON, SO I THINK
THIS IS JUST A WAIT AND SEE
ATTITUDE RIGHT NOW, THANK YOU.
>> THANK YOU DO YOU KNOW IF
THERE WILL BE OPEN COMMENT
OPPORTUNITIES FOR THAT?
>> PROBABLY SO.
MOST LEGISLATIVE EVENTS DO HAVE
OPPORTUNITIES.
THEY SAID ARE YOU AWARE OF
ANYTHING FORMAL?
>> IT DEPENDS ON WHETHER
ADDITIONAL HEARINGS ARE
SCHEDULED THAT WOULD INVITE
WITNESSES FROM THE PUBLIC.
A COUPLE ALREADY HAVE BEEN HELD
AND I BELIEVE I MENTIONED THOSE
THAT THE MAIN MEETING TO FOCUS
ON APPROPRIATION.
>> THANK YOU.
>> THANKS.
>> SO MY QUESTION WAS MORE ON
BUDGET IMPACT OF THE PROPOSED
FUNDING ON WHAT NLM IS ABLE TO
DO.
SO AGAIN, IT FALLS INTO THE SAME
RESPONSE AREA AS REORGANIZATION,
WE DON'T KNOW THE BUDGET LEVELS,
WE HAVE THE PRESIDENT'S
PROPOSAL, WHAT HISTORY HAS SHOWN
IS THAT PRESIDENT POSALS ARE
NEVER FUNDED AS PROPOSED,
THERE'S ALWAYS ADJUSTMENTS WITH
CONGRESS EVERY YEAR SO I DON'T
THINK THIS IS ANY DIFFERENT.
THIS IS JUST, YOU KNOW AN
ADMINISTRATION STATEMENT UNDER
PRIORITIES.
SO THAT BEING SAID, I THINK WE
HAVE TO WATCH THE PROCESS PLAY
OUT, NLM HAS DIRECTOR OF
NATIONAL INSTITUTE INTERNAL WORK
TO INSURE RESILIENCE IN OUR
OPERATIONS, WE TRY TO LOOK WITH
SUSTAINABILITY PLANS AT EVERY 1
OF OUR PRODUCTS AND SERVICES AND
OFFERINGS, AND TRYING TO
UNDERSTAND THAT WE ARE
DELIVERING MAXIMUM VALUE, AND
TAXPAYERS FOR THE INVESTMENT AND
YOU ARE TRYING TO -- OUR GOALS
OF SUPPORTING MEDICAL HEALTH
ACCELERATING RESEARCH, YOU KNOW
IMPROVING THE ECOSYSTEM, ALL THE
THINGS THAT WE █CHARGE TO DO ARE
BEING DONE EFFECTIVELY.
I THINK THAT'S THE BEST CASE WE
CAN MAKE FOR INVESTMENTS AND I
THINK IF THERE ARE CHANGES, THEN
WE CERTAINLY WILL BE TALKING
ABOUT THIS AT THE NEXT BOARD
MEETING AND WAIT AND SEE WHAT
THE PROCESS DELIVERS FOR
DELIBERATION.
>> OKAY, CHRISTIAN HAS A
QUESTION?
>> YEAH, I WAS JUST FOLLOWING UP
ON THAT.
I WAS JUST WONDERING IF YOU CAN
CONFIRM MY UNDERSTANDING THAT IF
SUCH A DRASTIC CUT WOULD HAPPEN,
IT WOULD COME WITH A LOT OF
INFORMATION ABOUT WHICH PROGRAMS
WOULD BE AFFECTED, HOW MUCH
FLEXIBILITY WOULD YOU HAVE IN
IMPLEMENTING THAT KIND OF A CUT?
AND I KNOW THAT'S A TOUGH
QUESTION.
>> YEAH, SO I MEAN WE'RE KIND OF
INTO THE WHAT-IF SCENARIO,
RIGHT?
I THINK THAT MESSAGING WILL BE
INCREDIBLY IMPORTANT.
THIS IS AN NIH LEVEL, JUST TO
SAY OVERALL THAT'S A LEVEL THAT
WILL IMPACT ALL SORTS OF
OPERATIONS AT NIH, NOT JUST NLM,
SO, YOU KNOW TO THE DEGREE THAT
THAT COMES WITH REORGANIZATION
OR WE DON'T GET REORGANIZED AND
THERE'S STILL SUBSTANTIAL CUTS
NIH WILL HAVE TO MAKE SOME WIDE
RANGING RESPONSES AND
COMMUNICATION AROUND WHAT'S
CHANGE NOTHING OUR RESEARCH
SERVICES PORTFOLIO AND ASSETS.
SO I THINK THE CHALLENGE WILL BE
HAVING NLMs CHANGES ALIGNED
AND EFFECTIVELY PACKAGED WITH
THAT COMMUNICATION.
SO WE'LL JUST, AGAIN, WE'RE
READY TO WORK ON THAT, IF THAT
IS THE FUTURE, YOU KNOW, MAYBE
THERE WILL BE A BUDGET INCREASE?
[LAUGHTER]
SO, WE'LL JUST SEE WHAT HAPPENS
>> THANK YOU, STEVE.
>> THANK YOU LOLA.
>> OKAY, SO, WE'RE GOING TO
WELCOME DIANE BABSKI NEXT
COLLECTOR OF COLLECTION SERVICES
AT THE NLM AND SHE WILL SHARE A
PROPOSAL TO ESTABLISH A BOARD OF
REGENTS WORKING BROWP TO ASSIST
WITH MED LINE MODERNIZATION.
>> OKAY, GOOD MORNING EVERYONE.
I SEE CRYSTAL HAS HIS HAND UP,
SORRY?
YOU'RE GOOD, OKAY?
SO GOOD MORNING, AND THANK YOU
FOR THE OPPORTUNITY TO PRESENT
TODAY.
CAN I JUDGE UOF THE GET A QUICK
THUMBS UP, CAN YOU SEE MY
SLIDES, EXCELLENT, THANK YOU.
I AM DIANE BABSKI, I'M DIRECTOR
OF USER SERVICES AND COLLECTION
DIVISION AT THE NATIONAL LIBRARY
OF MEDICINE AND TODAY I WOULD
LIKE TO INTRODUCE A PROPOSAL FOR
A BOARD MED LINE WORKING GROUP.
A GROUP THAT WILL HELP GUIDE A
THOUGHTFUL REENVISIONING OF 1 OF
NLM'S MOST ENDURING AND VALUED
PUBLIC RESOURCES.
SO LET'S TART FIRST WITH
DEFINING WHAT MED LINE IS, IF
YOU'VE USED PUB MED, YOU'VE USED
MED LINE.
IT'S A BIBLIOGRAPHIC DATABASE
WITH OVER 32 MILLION CURATED
CITATIONS TR FOR MORE THAN 5200
BIOMEDICAL JOURNALS, THESE
CITATIONS SUPPORT RESEARCH AND
CLINICAL DECISION MAKING POLICY
AND PUBLIC HEALTH.
BOTH NATIONALLY AND GLOBAL.
WHAT DISTINGUISHES MED LINE IS
THE TRUST IT CARRIES.
IT'S CAREFULLY CURATED, IT LINKS
TO OTHER AUTHORITATIVE RESOURCES
AND IT'S DESIGNED TO HELP PEOPLE
FIND THE RIGHT EVIDENCE FAST.
MED LINE'S VALUE GOES BEYOND
INCLUSION AND INDEXING OF
JOURNAL CITATION DATA.
IT INCLUDES MESH INDEXING,
MEDICAL SUBJECT HEADINGS, OUR
CONTROLLED VOCABULARY THAT
IMPROVES SEARCHING AND DATA
ACCESS POINTS.
IT LINKS TO CLINICAL TRIALS.GOV,
CONNECTING LITERATURE TO
CLINICAL STUDIES.
GENE AND PROTEIN DATA LINKS ARE
ADD THAT ALSO GO OUT TO OTHER
NLM DATABASES, OF COURSE NIH
FUNDING DATA TO SHOW WHO
SUPPORTED THE WORK AND POST
PUBLICATION UPDATES, SUCH AS
LINKS TO RETRACTIONS OR COMMENTS
TO HELP TRACK ARTICLE AND
INTEGRITY.
THESE VALUE ADDED FEATURES
IMPROVE DISCOVERABILITY, CONTEXT
AND AGAIN TRUST.
SO MEDLINE HAS EVOLVED
SIGNIFICANTLY OVER THE DECADES
AS YOU WILL SEE HERE.
SO LET'S GO BACK IN TIME TO 1870
AND IMAGINE JOHN SHAW-BUILTINGS
INDEXING JOURNALS FROM HIS HOME
AND THIS LAID THE FOUNDATION FOR
SYSTEMATIC ORGANIZATION OF
BIOMEDICAL LITERATURE.
JUMP TO 1879, AND THAT MARKS THE
BEGINNING OF MODERN MEDICAL
INDEXING WITH THE INDEX MEDICUS.
IN 1960, MESH, MLM'S SUBJECT
MEDICAL HEADINGS IS INTRODUCED
CREATING A HIERARCHICAL
INDECKING, AND IN 1960 MEDLARS
WAS LAUNCHED, IT WAS THE FIRST
COMPUTERIZED BIBLIOGRAPHIC
SYSTEM AT NLM.
MOVING ON TO 1971, MEDLINE WHICH
STANDS FOR MEDLARS ONLINE MARKED
THE DAWN OF DIGITAL AGE FOR
MEDICAL KNOWLEDGE DISCOVERY.
JUMPING FORWARD TO 1997,
SKIPPING A FEW LITTLE POINTS IN
HERE LIKE GRATEFUL MED AND I
THINK WE'RE HITTING THE
HIGHLIGHTS SO 1997 PUB MED
LAUNCHES AND BRINGS MEDLINE TO
THE INTERNET FOR FREE.
IN 2002, THE MEDICAL TEXT
INDEXER, THAT WE CALL NTI, OUR
FIRST MACHINE ASSISTED INDEX IS
INTRODUCED.
JUMPING FORWARD TO 2021, WE
MARKED 50th ANNIVERSARY OF
MEDLINE AND THE LAUNCH OF AN
UPDATED COMPREHENSIVE MEDLINE
WEBSITE, AND THEN IN 2022,
MEDLINE TRANSITIONS TO FULLY
AUTOMATED MESH INDEXING VIA NTIX
A NEURONET WORK MODEL TRAINED ON
MILLIONS OF CITATIONS.
SO LET'S TALK A BIT MORE ABOUT
WHAT MEDLINE IS AND HOW IT FIT
INTOS THE NLM LITERATURE
ECOSYSTEM.
MANY PUB MED USERS PROBABLY
DON'T EVEN REALIZE THAT 83% OF
THE CITATIONS IN PUB MED COME
FROM THE MED LINE DATABASE.
PUB MED ALSO INCLUDES CITATIONS
TO RECORDS FROM PMC PUB MET
CENTRAL, A FREE FULL TEXT
ARCHIVE OF BIOMEDICAL AND LIFE
SCIENCES JOURNAL ARTICLES, IT
ALSO CONTAINS MANUSCRIPTS
SUBMITTED BY AUTHORS TO COMPLY
WITH THE NIH PUBLIC ACCESS
POLICY, AND CITATIONS FROM BOOK
SHELF WHICH CONTAINS NECK TICAL
REPORT, SYSTEMATIC REVIEWS, PEER
REVIEWED BOOKS, CLINICAL
PRACTICE GUIDELINES AND
AUTOMONOGRAPHS, AS YOU CAN SEE
IN THE DIAGRAM, THERE IS SOME
OVERLAP BETWEEN THE CONTENTS OF
MEDLINE AND PMC AND BOOK SHELF
BECAUSE RESOURCES CAN BE INDEXED
OR ORCHIVED IN MORE THAN 1
DATABASE.
SO MEDLINE'S CURRENT STRUCTURE
AND STILL ORIENTED AROUND
TRADITIONAL PUBLICATION TYPES
LIKE RESEARCH ARTICLES, REVIEWS,
CASE REPORTS AND WE'RE
WONDERING, DOES THIS CAUSE A
DISCONNECT BETWEEN WHAT USERS
ARE LOOKING FOR, WHAT MODERN
PUBLISHING INCLUDES AND WHAT ARE
WE LIMITED BY WITH HOW MEDLINE
IS CURRENTLY STRUCTURED.
SO WE WANT TO WORK WITH OUR
BOARD MEMBERS TO CONDUCT NOT
JUST A REVIEW, BUT AN EVIDENCED
INFORM EXPLORATION ASKING THE
RIGHT QUESTIONS, SEEKING
MEANINGFUL INPUT AND ULTIMATELY
PRODUCING A REPORT THAT WILL
POSITION MEDLINE FOR THE NEXT 50
YEARS, REMAINING RELEVANT,
DELIVERING EXPECTED VALUE AND
DESIGNED FOR LONG-TERM
SUSTAINABILITY.
SO TO CARRY THIS OUT, WE NEED TO
FIRST UNDERSTAND USER NEEDS AND
BEHAVIORS, THROUGH DAY REVIEW
AND TARGETED ENGAGEMENT.
WE NEED TO EVALUATE JOURNAL
PARTICIPATION PATTERNS ACROSS
MEDLINE AND PUB MED CENTRAL TO
BETTER UNDERSTAND WHY JOURNALS
PURSUE INCLUSION IN EACH AND HOW
THAT INFLUENCES USER DISCOVERY.
WE NEED TO ALSO REASSESS
LITERATURE SELECTION,
WHOLISTICALLY AND OUR PROCESSES
FOR ONGOING MONITORING AND
RESILIENCE VIEW AFTER JOURNALS
ARE ACCEPTED INTO MED LINE, WE
ALSO NEED TO THINK ABOUT OUR
CURATION NEEDS WHAT'S MOST
IMPACTFUL IN INDECKINGING WHAT
ALINES MATTERS MOST WITH USERS.
ALSO REVIEW THE IMPACT OF VALUE
ADDED DATA SUCH AS THOSE THINGS
I MENTIONED BEFORE, LIKE
CLINICAL TRIAL LENGTHS, FUNDING
DATA, GENE AND PROTEIN
CONNECTIONS, WHAT'S BEING USE
EXCLUDE WHAT ARE WE MISS
THAGOREAN MIGHT BE USEFUL.
WE ALSO NEED TO CONSIDER HOW THE
WORLD OF BIOMEDICAL PUBLISHING
AND CHANGING.
THERE'S NEW ARTICLE FORMATS
EMERGING, AUTHORS EXPECTED TO
SHARE MORE ABOUT THE METHODS,
DATA SETS AND FUNDING, AND USERS
ARE SEARCHING DIFFERENTLY USING
AI TOOLS AND BOTS AND PLATFORMS
BEYOND PUB MED.
SO OVER THE NEXT 7 MONTHS WE'RE
ASKING FOR YOUR PARTNERSHIP IN
REENVISIONING MEDLINE, EACH OF
YOU BRINGS VALUABLE BE INSIGHTS
FROM YOUR COMMUNITIES, YOUR
DISCIPLINES AND YOUR METE YORKS
AND YOUR INPUT IS ESSENTIAL TO
INSURING THAT THIS EFFORT IS
INCLUSIVE STRATEGIC AND
SUSTAINABLE.
OUR END POINT IS A FINAL REPORT
CAPTURING VISIONS AND IDEA THAT
WILL HELP INSURE THAT MEDLINE
REMAINS AUTHORITATIVE AND
TRUSTWORTHY, RELEVANT IN TODAY'S
EVOLVING PUBLISHING LANDSCAPE,
RESPONSIVE TO THE DIVERSE NEEDS
OF OUR USERS, INTEROPERABLE AND
OPEN TO FEDERATED DISCOVERY SO
THAT MEDLINE CAN CONNECT MORE
SEAMLESSLY TO NIH AND BIOMEDICAL
PLATFORMS AND MOST IMPORTANTLY
SCALABLE AND SUSTAINABILITY
LEVERAGING AUTOMATION AND SMART
CURATION PRACTICES TO GROW
RESPONSIBLY WITHOUT COMPROMISING
QUALITY.
SO THIS IS A PIVOTAL MOMENT NOT
JUST FOR MEDLINE BUT THE FUTURE
OF HOW WE CONNECT OUR USERS TO
TRUSTED BIOMEDICAL LITERATURE.
TO INSURE MEDLINE CONTINUES TO
FULFILL ITS MISSION, WE NEED TO
REEXAMINE THE SCOPE, CURATION
AND COVERAGE SO IT CAN EVOLVE
ALONGSIDE, THIS SCIENTIFIC
PROCESS AND RISE TO MEET THE
NEEDS OF TODAY'S RESEARCHERS,
CLINICIANS AND LIBRARIES AND
OTHER STAKEHOLDERS.
TOGETHER WE HAVE THIS
OPPORTUNITY TO SHAPE A MEDLINE
THAT IS NOT ONLY RELEVANT AND
RESPONSIVE BUT RESILIENT.
A RESOURCE THAT WILL CONTINUE
FOR ANOTHER 50 YEARS, TO ADVANCE
DISCOVERY AND INFLUENCE
INNOVATION FOR GENERATIONS TO
COME.
SO THAT IS MY TIME AND I WILL
OPEN THE FLOOR TO QUESTIONS.
>> THANK YOU SO MUCH DIANE, I
ESPECIALLY ENJOYED THE HISTORY
OF MEDLINE AND INDEXING.
I WILL ASK PHILLIP WALKER AND
CHRIS SHAFFER TO HELP LEAD THE
DISCUSSION/QUESTIONS.
>> I WILL GO AHEAD AND KICK IT
OFF THEN, I'M REALLY EXCIDED
ABOUT THIS INITTIAIVE IT AND HI,
DIANE IT'S SO NICE TOY SLEEP
APNEA AND OBESITY YOU AGAIN AND
YES, I REMEMBER QUITE A FEW OF
THE MORE DETAILED PIECES OF THE
HISTORY, LIKE GRATEFUL MED, AND
INTERNET GRATEFUL MED FROM BACK
IN THE DAY SO I WAS WONDERING IF
YOU COULD COMMENT A LITTLE BIT
ABOUT WHAT'S MEANT BY COVERAGE
AND SCOPE OF MEDLINE IN THIS
CONTEXT?
IS THAT FOCUSED LARGELY ON
FORMATS AND ARTICLE TYPES AND
THINGS LIKE THAT, SORE DOES IT
-- DOES IT INCLUDE CONTENT
COVERAGE AS AN EXAMPLE.
AND ALSO, HOW IS THAT GOING TO
INTERACT WITH THE NIH DATA
MANAGEMENT SHARING PLAN.
>> YEAH, EXCUSE ME, SO CHRIS HAS
A FEW AS WELL AND I HAD TO
CONTROL MYSELF WITH HOW MANY
DIFFERENT THINGS I INCLUDED IN
THE HISTORICAL OVERVIEW, SEE I
APPRECIATE YOUR COMMENTS ON
THAT.
YES, YES, AND YES.
WE ARE LOOKING AT -- WE REALLY
WANT TO TAKE AN INDEPTH ANALYSIS
OF WHAT WE CURRENTLY HAVE IN
MEDLINE AND WHERE WE NEED TO GO
BOTH WITH THE SCOPE OF THE
DIFFERENT TYPES OF JOURNALS WE
COVER.
DIFFERENT ARTICLE TYPES AND
THINGS LIKE THAT, WE GO THROUGH
NOW, AND YOU KNOW WE TRY TO
STICK TO ORIGINAL -- YOU KNOW
RESEARCH ARTICLES, REVIEWS AND
CASE REPORTS AND THINGS LIKE
THAT, AND WE ASK PUBLISHERS NOT
TO ADD A LOT OF OTHER ARTICLE
TYPES AND THINGS IN THERE, DOES
THAT AFFECT OUR SEARCHERS, DO
THEY EVEN KNOW IT'S NOT THERE,
SO IT'S REALLY LOOKING
COMPREHENSIVELY ACROSS WHAT HAVE
WE DONE IN THE PAST TALKING TO
OUR USERS TO FIND OUT, DO YOU
EVEN KNOW WHAT YOU'RE NOT
GETTING ACCESS TO, AND DO YOU
MISS IT, AND YOU KNOW HOW WILL
THAT IMPACT DISCOVERIABILITY
ACROSS NOT ONLY PUB MED BUT
ACROSS OTHER PLATFORMS AND
SYSTEMS.
REMIND ME AGAIN WHAT WAS YOUR
QUESTION ABOUT THE PUBLIC
ACCESS?
>> I THINK THAT'S FINE.
SO, YOU ACTUALLY LED TO MY
SECOND QUESTION WHICH IS THIS IS
A PRETTY PROGRESSIVE TIMELINE
HOW DO YOU ANTICIPATE END USER
ENGAGEMENT OCCURRING DURING
THIS?
>> YEAH, SO WE ALREADY PUT A
LITTLE JUMP START ON THIS WITH
OUR NLM STAFF, WE HAVE 3 WORKING
GROUPS INTERNALLY STARTED
LOOKING AT DIFFERENT PIECES OF
THIS AND EACH IS MOVING FORWARD
WITH REVIEWING A LOT OF OUR USER
DATA AND ANALYZING THAT WILL BE
PUTTING -- WORKING WITH A LOT OF
OUR DIFFERENT ADVISORY GROUPS
AND EXTERNAL STAKEHOLDERS TO GET
COMMENTS AND AGAIN THIS IS GOING
TO BE A REPORT TO ENVISION WHAT
MEDLINE IS, SO IT'S NOT
ACTUALLY, IT'S AN END PRODUCT OF
A REPORT FOR WHERE WE REQUEST GO
WITH THIS, IMPLEMENTING IT WILL
BE ANOTHER DIFFERENT TIMELINE
ON, YOU KNOW DEPENDING ON WHAT
IT LOOKS LOAMACYIC AND HOW MUCH
CHANGE THERE IS AND DIFFERENT
SYSTEMS THAT IT WILL IMPACT.
>> THANKS, I WILL HAND IT OVER
TO PHILLIP NOW.
>> HI, DIANE, I HAVEN'T SEEN
EACH OTHER SINCE THE MOZUL
MENTOR -- CAP STONE, I'M EXCITED
ABOUT THIS AS WELL, IN ADDITION
TO BEING A DIRECTOR, I'M STILL A
SEARCH ADDICT AND I STILL LIKE
TO PLAY LIBRARIAN EVERY NOW AND
THEN WHEN I'M NOT IN MEETINGS
AND I WILL SAY DISCOVERABILITY
HAS BEEN A BIG PET PEEVE,
PARTICULARLY, I SEE THIS ALSO AS
AN OPPORTUNITY TO REALLY SET A
HIGHER STANDARD WITH SOME OF OUR
PUBLISHERS BECAUSE I THINK THE
JOURNAL OF MEDICAL EDITORS COULD
USE SOME HAD HERE, CASE IN PINT
IS THAT THERE AT LEAST I KNOW A
HUGE NEED, HUGE DESIRE
ESPECIALLY FROM OUR
PRACTITIONERS AND PROVIDERS THEY
WANT TO GO IN AND FIND
SYSTEMATIC REVIEWS BECAUSE THEY
CANNOT GO IN, OR THEY WANT TO DO
CLINICAL QUERIES BECAUSE THEY
CANNOT GO IN AND READ 10, 20, 70
ARTICLES, THERE ARE SO MANY
REVIEWS OUT THERE, IT'S GREAT,
BUT IT'S BECOMING WATERED DOWN
THOUGH, AT THE SAME TIME, YOU
KNOW THAT PUTS THE PRESSURE UPON
WHAT THE EDITORS JUST BECAUSE
YOU DID A SYSTEMATIC REVIEW OF
THE LITERATURE DOESN'T MEAN YOU
DID A SYSTEMATIC REVIEW AND THAT
DEFINITELY NEEDS TO BE REVISED I
THINK AND STARTS AT THE JOURNAL
LEVEL AND HOW IT BECOMES HERE IS
THAT DISCOVERY AND AS WE REALLY
GO THROUGH THIS EVALUATION
PROCESS, AND TO UNDERSTAND USER
BEHAVIOR BECAUSE I'M SITTING
HERE LISTENING TO THIS AND
TAKING NOTES AND I'M THINKING
ABOUT ALL THE QUESTIONS I'M
GETTING ABOUT THESE NEW AI
LITERATURE TOOLS I CAN'T TELL
YOU HO YOU MANY QUESTIONS I'VE
BEEN GETTING ABOUT CONSENSUS AND
LISTED AND OPEN EXPEFDZ
EVERYTHING LIKE THAT AND HOW I
GUESS YOU COULD SAY THE VENTURE
CAPITAL AND ALL THE COLLEGE
STUDENT WHO IS WERE TOO LAZY TO
WRITE PAPERS IN COLLEGE, THEY
DECIDE, I WILL USE AI AND START
ALL THESE NEW TOOLS AND GO GRAB
MONEY OUT OF SILICONE VALLEY.
SO I THINK THIS IS A GOOD WAY TO
THINK, I KNOW THERE'S
LIMITATIONS OF KOWRGS WITH PUB
MED AND CITATIONS IN ABSTRACT
VERSUS PMC, BUT HOW IS IT THAT
WE CAN IMPROVE DISCOVERABILITY
BASED UPON THE EVOLUTION OF THIS
EVIDENCE ECOSYSTEM.
NOW GRANTED WE HAVE YOUR BASIC,
STUDENTS, RESEARCHERS AND
CLINICAL PROVIDERS AS WELL ALL
THE WAY FROM PATIENT TO
POPULATION HEALTH SO THERE'S A
GOOD MIX OF COHORTS THAT NEED TO
BE TAKEN INTO CONSIDERATION
HERE, BUT I DO THINK NOT ONLY AS
THE LITERATURE HAS EVOLVED I
BELIEVE IT HAS REGRESSED IN SOME
AREAS, WAT THE SAME TIME USER
EXPECTATIONS NOW, WITH
GENERATIVE AI IS THE LAST TIME
WE WERE TOGETHER, WE WERE
DISCUSSED, OF HOW, -- HOW THAT
CAN ALSO PLAY INTO A ROLE HERE.
I'M NOT GETTING FANCY WITH THESE
GRAFS AND ALL THAT OTHER STUFF,
THAT SEEMS TO BE, YOU KNOW, BUT
RIGHT NOW, HOW IMPROVING
DISCOVERABILITY AND MANAGEMENT
IS GOING TO BE A BIG FACTOR
ESPECIALLY, I WILL SPEAK FOR MY
OWN CLINICAL SIDE, THAT'S THE
BIGGEST PROBLEM I'M SEEING AND
WYOMING, SO, WE'VE GOT THE
TRUSTWORTHINESS, THAT'S THE
ADVANTAGE WE HAVE WITH MEDLINE
AND THE FACT THAT HAVING
37 MILLION ARTICLES OR CITATIONS
AND ABSTRACTS, VERSUS HOW SOME
OF THESE PRODUCTINGS ARE
BRAGGING THAT THEY HAVE 100 OR
SOMETHING, 200 MILLION ARTICLES
WHICH ALMOST SOUNDS LIKE THE
NAPSTER LITERATTIZATION
NOWADAYS, BUT WE STILL HAVE THE
TRUSTWORTHINESS AND HOW DO WE
UNDERSTAND WHAT THE USERS ARE
DOING NONAPOPTOTIC THE
GENERATIVE AI NOW AND HOW THAT
CAN HELP WITH NOT ONLY
DISCOVERABILITY BUT I THINK WE
ALSO HAVE TO BEGIN THINKING
ABOUT THAT KIND OF
SUMMERRIZATION ASPECT OF IT AS
WELL, AND WILL LIKE AND I WILL
CONCLUDE, I KNOW WE'RE OVERTIME,
I DO LIKE WHAT DR. LEONARD SAID
IN THAT ARTICLE ABOUT THE NLM
AND ERA OF AI ABOUT REALLY
THINKING ABOUT THAT OBSERVATORY
CONCEPT I THINK THAT COULD ALSO
PLAY A ROLE INTO THIS, THIS
PROPOSAL AS WELL.
>> EXCELLENT, THANK YOU.
>> ARE THERE ANY QUESTIONS FROM
ANY OTHER BOARD MEMBERS?
>> SO THANK YOU SO MUCH DIANE
AND LOOK FORWARD TO HEARING MORE
ABOUT WHERE THIS GOES.
>> EXCELLENT, THANK YOU.
>> SO NOW IS KATHRYN FARRELL,
ON?
>> SO DIANE CAN STOP SHARING
SLIDES SO I CAN.
>> SORRY, 1-SECOND.
>> SO WHILE THE SLIDES ARE
CHANGED, I WANT TO WELCOME
DR. KATHRYN FARRELL PROGRAM
OFFICER FROM THE NLM'S DIVISION
OF EXTRAMURAL PROGRAMS AND SHE
WILL PRESENT A CONCEPT CLEARANCE
FOR ADVANCING BIO-INFORMATICS --
TRANSLATIONAL BIO-INFORMATICS
AND COMPUTATIONAL BIOLOGY
RESEARCH AND I HOPE I PRONOUNCE
YOUR LAST NAME RIGHT.
>> SO THANK YOU FOR THE
INTRODUCTION, I AM JUST CHECKING
CAN EVERYBODY SEE THE SLIDES
OKAY.
>> OKAY, SO I'M A PROGRAM
OFFICER FROM NLM'S DIVISION OF
EXTRAMURAL PROGRAMS AND ALSO
CONCEPT CLEARANCE, AND
COMPUTATIONAL BIOLOGY RESEARCH,
TO PROVIDE YOU SOME BACKGROUND
NLM HAS BEEN A LEADER IN
INFORMATION SCIENCE THAT
SUPPORTS KEY EXTRAMURAL RESEARCH
AREAS AND BIOMEDICAL INFORMATICS
AND DATA SCIENCE WITH CURRENT
SPECIFIC FOCUS AREAS DM DATA
SCIENCE, BIO-INFORMATICS AND
TRANSLATION OF COMPUTATIONAL
BIOLOGY, PUBLIC HEALTH
INFORMATICS AND CLINICAL
INFORMATICS AND PERSONAL HEALTH
UPON INFORMATICS.
FROM BASIC RESEARCH TO APPLIED
RESEARCH AND PRACTICE, AND THE
SPANS THE RANGE FROM MOLECULES,
CELLS, TISSUES AND ORGANS TO
PATIENTS, CLINICIANS,
INDIVIDUALS AND POPULATIONS.
BIOLOGY CENTRIC AREAS ARE THE
FOCUS OF THIS CONCEPT CLEARANCE
FOR THE REST OF THIS
PRESENTATION THE FOCUS ON
BIO-INFORMATICS COMPUTATIONAL
BIOLOGY AND TRANSLATIONAL
BIO-INFORMATICS KEY RESEARCH
AREAS.
THESE RESEARCH AREAS INVOLVE THE
DEVELOPMENT OF METHODS AND
SOFTWARE TOOLS FOR ANALYZING AND
NLDING BIOLOGICAL DATA.
THEY HAVE AREAS OF SHARING
BIOLOGIC DATA FOR PHYSICS,
CHEMISTRY, PROGRAM
INFORMATIONING, COMPUTATIONAL BI
OLINGS AND TRANSLATION
BIO-INFORMATICS.
BIO-INFORMATICS ARE PREDOMAIN
NATALIE SEQUENCED BASE OR OMICS
RESEARCH, COMPUTATIONAL BIOLOGY
IS A INTERSECTION OF BIG DATA
AND MAY INCLUDE CELLULAR
ERGANISM OR POPULATION-LEVEL
STUDIES FOR TRANSLATION OF
BIO-INFORMATICS BRIDGES
BIO-INFORMATICS STRUCTURAL
INFORMATICS AND CLINICAL
INFORMATICS TO EXPLAIN AND
PREDICT CLINICAL PHENOMENA.
FOR MANY YEARS NOW, NLM HAS BEEN
SUPPORTING INNOVATION RESEARCH
AND BIO-INFORMATICS, AND
COMPUTATIONAL BIOLOGY, NLM
CURRENTLY FUNDS RESEARCH AND
THOSE IMPORTANT CORE AREAS OF
BIOMEDICAL INFORMATICS, UMBRELLA
FOR THE OPPORTUNITY ENTITLED NLM
RESEARCH GRANTS AND
BIO-INFORMATICS AND DATA
SCIENCE, THAT NEW AND INNOVATIVE
APPROACH IS TO FOSTER
INFOIVATIVE DISCOVERY AND
RESEARCH ACROSS THE MEDICAL,
BIOLOGICAL AND CLINICAL AND
HEALTH SIDES, HOWEVER, THAT NOFO
WILL EXPORE ON MARCH OF NEXT
YEAR THEREFORE NEW FUNDING
PROGRAMS NEED TO BE DEVELOPED
FOR CONTINUED NLM SUPPORT OF
RESEARCH IN CORE AREAS OF
BIOMEDICAL INFORMATICS.
HENS THIS CONCEPT CLEARANCE
FOCUSING ON COMPUTATIONAL
BIOLOGY RESEARCH.
FOLLOWING MY PRESENTATION MY
COLLEAGUE WILL PRESENT A CONCEPT
CLEARANCE FOCUSING ON
INFORMATICS RESEARCHERS.
SO INDEPTH CATEGORIZATION OF A
SUBSET OF NLM PROJECT RESEARCH
GRANTS OVER THE PAST DECADE
INDICATED WIDE RANGE OF
BIO-INFORMATICS TYPE,
SUBCATEGORIES ARE OF COMMUNITY
INTEREST, AS SHOWN IN THE PIE
CHART THOSE SUBCATEGORIES
INCLUDE VARIOUS SIDES OF OMICS
AND MULTIOMICS PROJECTS,
MICROBIOME AND GENOMICS
PROJECTS, PROJECTS THAT USE AI
OR MACHINE LEARNING APPLICATIONS
FOR PREDICTABLE BIOINFORMATIC
RESEARCH, COMPUTATIONAL BIOLOGY
DEVELOPMENT OF,AINAL SIS OF
GENOMICS NONGENOMIC BIOLOGICAL
FOM NATIONAL LIBRARY -- PHENOMS
FUNCTIONAL GENOMIC PROJECTS.
FURTHER MORE THE PORT FOAL
INCLUDES TRANSFORMATION OF
PROJECTS INVOLVING STORAGE AND
INTERPRETATIVE TO BRIDGE
BIOLOGICAL INFORMATICS AND
EXPLAIN CLINICAL PHENOMENA; FROM
PORTFOLIO ANALYSIS,
BIO-INFORMATICS AND
COMPUTATIONAL BIOLOGY TYPE
PROGGENTS FOR FISCAL YEAR 2024,
WE STARTED THE NLM RECEIVED 49
APPLICATIONS FOR RESEARCH
PROJECTS IN THOSE AREAS
CORRESPONDING FOR APPROXIMATELY
21% RESEARCH PROJECT
APPLICATIONS RECEIVED.
THE COMMUNITY'S RESEARCH IN
THOSE PHASE AND SIGNIFICANT
PROPORTION REPRESENT IN THE
BROAD NLM GRANTS FORT FOLIO.
FOLLOWING THOSE APPLICATIONS
MRIIDATIONS THAT WERE AWARDED
INDICATING SUBASSESSES RISK OF
2%, JUST SLIGHTLY BELOW THE
AVERAGE OF 11.9% FOR ALL
RESEARCH PROJECTS IN
APPLICATIONS RECEIVED BY NLM IN
FISCAL YEAR 24.
IN FISCAL YEAR 23,
BIO-INFORMATICS OR COMPUTATIONAL
BIOLOGY PROJECTS WERE
APPROXIMATELY 21% OF RESEARCH
GRANTS AWARDED AND INDEED GOING
BACK OVER THE LAST DECADE IT'S
ALSO TRUE THAT ABOUT MORE THAN
EVERY 5 RESEARCH PROJECTS
GRANTED AWARDED FROM FROM
BIO-INFORMATICS OR COMPUTATIONAL
BIOLOGY TYPE CATEGORIES.
THEREFORE WE CAN CONCLUDE THERE
IS COMMUNITY INTEREST IN
CONTINUED NLM'S 1 THING OF
RESEARCH IN THOSE CORAREAS OF
BIOMEDICAL INFORMATICS.
QUALITATIVE ASSESSMENTS WERE
CARRIED OUT TO IDENTIFY GAPS AND
SCIENTIFIC STRENDS IN
BIO-INFORMATICS AND BIOLOGY TYPE
PROJECTS IN THE CURRENT NLM
GRANTS FORT POLIO.
THE THIS SHOWS GRAPS
CORRESPONDING WITH THAT, IN THE
SINGLE DISCIPLINE PROJECTS THAT
ARE INFORMED BY DATA AND OUR
APPROACHES WITHIN THAT
PARTICULAR DISCIPLINE WHEREAS
PROJECTS APPLYING
INTERDISCIPLINARY APPROACHES TO
LEVERAGE KNOWLEDGE FROM RELATED
DISCIPLINES WILL BE MORE
DESIRABLE.
ANOTHER IDENTIFIED TREND IS
PROGGENTS THAT PRODUCE THISAD
HOC PRODUCTS ARE PRODUCTS THAT
ARE AT LARGER WORK OF THOSE
WHERE,A PROACHS RESULT IN WHOLE
USEABLE PIPELINE OR RESOURCES
WORTH REPRESENT THEIR FUTURE
FUNDING.
>> ANOTHER TREND IN THE CURRENT
PORTFOLIO IS PRODUCT GEPMENT
COMPETENCIES UNDER RELATED
FUNDED PROJECTS WHEREAS PROJECTS
CAN BE EVALUATED APPLIED AND
DISSEMINATED IN THE PROJECTS FOR
GOING FORWARD.
ADDITIONALLY SOME OPPORTUNITIES
OF FUTURE NEED WERE WAIRKS
DENTIFIED FROM ANALYZING THE
STATE OF THE BIO-INFORMATICS OF
THE COMPUTATIONAL BIOLOGY AND 1
SUCH OPPORTUNITY WILL BE FOR
CUTTING EDGE AND NEW
TECHNOLOGIES THAT ARE LIKELY
PRODUCE MEANINGFUL ADVANCES AND
THAT WOULD BE TO INCORPORATE
EMERGING AREAS OF
BIO-INFORMATICS AND
COMPUTATIONAL BIOLOGY THAT ARE
AGAINING IN PROMINENCE, IN
ADDITION IT'S KNOWN THAT THE
HIGHLY COMPLEX AND VOLUME NOWS,
AND SCORED A CONTINUED NEED TO
HARNESS THE POWER OF INNOVATIVE
TECHNOLOGIES TO TRANSFORM BIG
DATA INTO KNOWLEDGE, WHICH COULD
THEN BE IMPLIED TO BE APPLIED TO
INFORM HEALTH OUTCOMES.
THEREFORE, FOR THIS PROPOSE
NOTICE OF FUNDING OPPORTUNITY,
THE OVERARCHING AIM WILL BE TO
DRIVE GROUND BAKING INNOVATION
AND DEVELOPMENT IN THE
BIO-INFORMATICS AND TRANSLATION
OF BIO-INFORMATICS AND
COMPUTATIONAL BIOLOGY NEEDS, AND
WITH THAT THAT PUSHED THE
BOUNDARIES OF DISCOVERY AND
PROVIDE MEANINGFUL ADVANCEMENTS
IN BIOLOGICAL RESEARCH.
THE PROPOSED FUNDING MECHANISM
IS THE RO-1 RESEARCH PROJECT
GRANT.
THE NEW NOFO WITH THE SPECIAL
EMPHASIS ON INFOIVATIVE --
INNOVATIVE METHODS AND
TRANSFORMATIVE TECHNOLOGIES SUCH
AS AI AND LARGE SCALE IMAGING
AND AUTOTON MOUSE PERFORMANCES
ARE IDENTIFIED FROM THE CURRENT
PORTFOLIO AND AS PRESENTED IN
THE PREVIOUS SLIDE.
TOPICS OF INTEREST WOULD INCLUDE
THE BIO-INFORMATICS CATEGORIES
THAT ARE ALREADY IN THE NLM
GRANTS PORTFOLIO AND THE
REGIONAL LEVEL AT
BIOINFORMATTICS AND CELLULAR
ORGANISM AND POPULATION OF
COMPUTATIONAL BIOLOGY PROGETHS
AS SHOWN IN THE PREVIOUS SLIDE.
THIS IS ALSO SPECIAL INTEREST IN
TRANSLATION APPROACHES, AND IN
UP AND COMING TOPICS.
ADVANCEMENTS COULD DRAW FROM
INNOVATIONS IN MULTIPLE
DISCIPLINES INCLUDING BIOLOGY,
CHEMISTRY, PHYSICS, COMPUER
SCIENCE, BIODATA IMAGING,
MATHEMATICS OR STATISTICS,
RESEARCH OUTPUTS ARE EXPECTED TO
BE TRANSFORMATIVE AND
GENERALIZABLE, AND INITIAL POSTS
ARE DATA DRIVEN DISCOVERY TO
ACCOMPLISH RELATED TO RELATED
GOALS.
THIS SLIDE SHOWS TOPICS OF
INTEREST WILL INCLUDE PORTFOLIO
GAPS WE WOULD LIKE TO EMPHASIZE
SUCH AS INTERDISCIPLINARY
APPROACHES THAT ARE INFORMED BY
FUNCTIONAL BIOLOGY AND ARE
BIOMEDICAL DATA, APPROACHES THAT
RESULT IN WHOLE USEABLE PIPELINE
WORK LOADS OR RESOURCES RATHER
THAN SOFTWARE PRODUCTS THAT JUST
PERFORM FUNCTIONS IN THE
LARGER WORK FLOW, OR CHOOSE
MANAGES THAT CAN BE DEVELOPED
AND APLOYED EVALUATED AND
DISSEMINATED WITHIN THE SCOPE OF
THE PROPOSED PROJECT, WHICH AND
WHICH ARE DURABLE AND
AUTONOMOUSLY UPDATABLE.
FOR EXAMPLE OTHER EXAMPLES OF
TOPICS ARE WORK FLOWS, AND
INTEROPERABILITY AND WHICH ARE
EASILY FINDABLE BY THE WIDE
RESEARCH COMMUNITY AND WELL
DOCUMENTED USER FRIENDLY
PUBLICATIVE RESOURCES HA WHICH
ENCOMPOSES ETHICAL
REPRESENTATIONS FOR DOWN STREAM
USE.
OTHER INTERESTS WILL INCLUDE
TRANSLATION OF BIOINFORMATIC
APPROACHES THAT HAVE BROADLY
ADAPT ABLE AND GENERALIZABLE OF
GROWTH AND TRANSLATABLE THAT
CONTRIBUTE TANGIBLE FUNCTIONAL
KNOWLEDGE FOR DOWN STREAM USE,
OR COMPUTATIONAL OR OTHER MODELS
THAT ARE ADAPTABLE AND
DEVELOPMENTAL AND TESTABLE FOR
THIS DATA.
SO THOSE REPRESENT JUST THE
SAMPLING OF POTENTIAL INTEREST
AND MANY OTHER POSSIBILITIES
THAT WILL BE IN SCOPE FOR THIS
NEW FUNDING OPPORTUNITY.
REGARDING EXPECTATIONS FOR THIS
PROPOSED FUNDING INITIATIVE, IT
WILL ENABLE NLM TO CONTINUE
SUPPORTING AND THE DEVELOPMENT
OF CUTTING EDGE INNOVATIVE
METHODOGGOLOGYS TO AEMPLOY
COLISH ADVANCEMENTS ACROSS THE
BIO-INFORMATICS AND
COMPUTATIONAL BIOLOGIES.
IT WOULD SUPPORT OF THE CURRENT
NLM STRATEGIC PLAN BY DISCOVERY
AND ADVANCING HEALTH THROUGH
DATA DRIVEN RERESEARCH AND THOSE
AREAS OF BIOMEDICAL INFORMATICS
AND THIS TEXT OF THE STRATEGIC
1.
THE PROPOSED FUNDING OPPORTUNITY
WILL ADDITIONALLY ALIGN THE
GOALS FROM OTHER NIH OR DHHS
INITTIAIVE ITS INCLUDING GOALS
OF THE NIH OFFICE OF DATA
SCIENCE STRATEGY, THE NIH COMMON
FUNDS BRIDGE TO AI PROGRAM, AND
ALSO AI GOAL WITH THE DEPARTMENT
OF HEALTH AND HUMAN SERVICES.
THE PROPOSED NEW FUNDING
INITIATIVE IS SUPPOSED TO BE A
VARIETY OF STAKEHOLDERS,
INCLUDING BIOMEDICAL
RESEARCHERS, BIOCLINICAL
PERSONNEL OR EVEN PATIENTS OF
FOR TRANSLATION OF BI ON O
INFORMATICS RESEARCH.
IT'S ANTICIPATED THAT NLM WILL
PROVIDE 250,000 INDIRECT COSTS
PER YEAR FOR A MAXIMUM OF 4
YEARS FOR UP TO 10 AWARDS EACH
YEAR DEPENDING ON AVAILABILITY
OF FUNDS.
SO WITH THAT, I CONCLUDE MY
PRESENTATION AND OPEN THE FLOOR
FOR DISCUSSION, BUT I DO WANT TO
THANK ALL MY COLLEAGUES IN THE
EXTRAMURAL PROGRAMS FOR ONGOING
DISCUSSIONS, ASSISTANCE WITH
PORTFOLIO ANALYSIS AND
BRAINSTORM THAGOREAN -- BRAINST
CONTRIBUTED TO THIS.
AND FINALLY THANKS TO THE BOARD
AND ATTENDEES FOR LISTENING
TODAY.
>> THANK YOU SO MUCH KATHRYN.
I WILL NOW HAVE ANN AND RASMUS
LEAD THE DISCUSSION.
>> ANN WOULD YOU LOAMACYIC TO GO
FIRST?
>> YOU GO AND I WILL FOLLOW UP.
>> OKAY, SO THANKS SO MUCH IF
ARE THIS PRESENTATION, I THINK
THIS IS AN INCREDIBLY IMPORTANT
AREA OBVIOUSLY, THE BIOMEDICAL
RESEARCH HAS REALLY CHANGED FOR
THE PAST 20 YEARS AND SO MANY
BIOLOGICAL DISCOVERIES HAVE BEEN
DRIVEN BY BIG DATA THAT IN MANY
CASES, ARE DRIVEN BY NEW
COMPUTATIONAL METHODS AND
BIOMEDICAL METHODS SO KEEP
THAGOREAN RESEARCH GOING, I
THINK IS REALLY, REALLY
IMPORTANT IN BIOMEDICAL RESEARCH
FOR THE NEXT DECADES.
ONE THING I WANT TO -- SO I
APPLAUD YOU FOR THIS, IT WAS
FANTASTIC AND A GREAT NOFO, BUT
1 AREA THAT I JUST WANT TO POINT
OUT TO MANY OF MY COLLEAGUES
THAT'S DIFFICULT TO GET FUNDING
FOR IS THE CONTINUED MAINTENANCE
OF SUCCESSFUL EXISTING SOFTWARE,
SO THE WAY IT WORKS IN THE
COMPUTATIONAL ECOSYSTEM IS THAT
A LOT OF DEPENDENCIES, YOU
KNOWERING CHANGES ALL THE TIME,
YOU HAVE TO MAINTAIN THE
SOFTWARE, AND MOST AGENCIES LIKE
TO GIVE MONEY TO NEW INNOVATIVE
RESEARCH FOR GOOD REASONS, MONEY
SHOULD BE GIIVE TO THAT BUT FOR
REASONS ALSO TO GET MONEY TO
MAINTAIN EXISTING SOFTWARE THAT
ALREADY HAS BEEN PROVEN REALLY,
REALLY USEFUL IF ARE BIOMEDICAL
RESEARCH, SO I WILL ENCOURAGE
THINKING ABOUT HOW IT MIGHT ALSO
BE POSSIBLE TO SUPPORT THAT KIND
OF ONGOING RESEARCH ON EXISTING
WELL ESTABLISHED PIPELINES AND
COMPUTATIONAL TOOLS.
>> YES, THANK YOU FOR THAT.
WE WILL BE ENCOURAGING THE NOFO
TO PRODUCE LIKE DURABLE PRODUCTS
THAT CAN BE UPDATED, MAINTAINED
AND YOU KNOW HOPEFULLY, THE NEW
TECHNOLOGIES LIKE AI WILL BE
ABLE TO ACCESS THERE AND
INCORPORATE NEW SCIENCE.
AND YOU KNOW OBVIOUSLY DATA
SHARING AND USE ACROSS THE
COMMUNITY WILL BE A VERY
IMPORTANT ASTHMAPOLIS -- ASPEC.
>> ALSO THE MAINTENANCE OF
EXISTING COMPUTATIONAL TOOLS
THAT ALREADY ARE PART OF THE
ECOSYSTEM, THAT THE CONTINUED
MAINTENANCE OF THEM WAS ALSO
DIFFICULT TO FIND FUNDING FOR.
>> YEAH, I THINK SUSTAINABILITY
IS ALWAYS A CHALLENGE AND HAVING
SOME SORT OF SOME SORT OF
MECHANISM FOR SUSTAINABILITY IS
REALLY IMPORTANT ACTUALLY AND I
HAVE SORT OF A, I HAVE A RELATED
QUESTION, I LOVE THE FOCUS ON
INTERDISCIPLINARY, AND MULTIPLE
PIs, IS THERE ANY KIND OF
PROGRAM OPPORTUNITIES IN THE
HORIZON, ANYTHING LIKE THAT, IN
THIS VISION?
>> WE WOULD ENCOURAGE
COLLABORATIONS AND IN FACT IT'S
VERY COMMON IN OUR CURRENT
PORTFOLIO THAT WE DO HAVE THAT,
BOTH OF THAT, BUT WE WOULD
REALLY LIKE TO SEE, YOU KNOW
CROSS CUTTING PROGRESS SO THAT
THERE'S INTEROPERABILITY AND
DISCIPLINES ACROSS CUTTING
PROCESS SO THAT LIKE WE HAVE A
LOT OF PRODUCING LOTS OF MAPS
AND THINGS LIKE THAT BUT MAYBE
THE BIOLOGY WASN'T VERY WELL
CONSIDERED FOR EXAMPLE, OR MAYBE
THE CLINICAL OCCUPATIONS WEREN'T
SO WELL, OR THERE WASN'T ENOUGH
CLINICAL PRESENTS ON THE TEAM,
SO WE WILL LOOK AT THAT.
>> HAD 1 MORE THOUGHT ON YOU
KNOW THE SUSTAINABILITY ISSUE IS
IT ALWAYS A CHALLENGE AND I'M
WONDERING IF THERE ARE
OPPORTUNITIES FOR THESE TYPES OF
PROGRAMS AND THE DELIVERABLES TO
BE PUT INTO AN ECOSYSTEM THAT
WILL BE SORT OF CENTRALLY
MAINTAINED.
THERE ARE SOME FUNDING
OPPORTUNITIES FROM THE OFFICE OF
DATA SCIENCE ODSS, FOR SOFTWARE
SUSTAINABILITY, BUT WE WANT TO
FOCUS ON THIS TO BE ON
INNOVATION AND RESEARCH, RATHER
THAN JUST GOING ABOUT PRODUCING
FOODS BUT WE WANT TO BE WHERE
POSSIBLE TO INTEGRATE SOME SORT
OF A SUSTAINABILITY, YOU KNOW
GRANT APPLICATION THAT DO HAVE
THAT AND WOULD LIKELY SCORE
BETTER?
>> IS THAT SOMETHING THAT YOU
COULD PUT IN THAT THE
EXPECTATION IS THAT THE SOFTWARE
WILL BE PUT INTO 1 OF THE
AVAILABLE ECOSYSTEMS.
THERE'S SEVERAL OF THEM AT THE
DIFFERENT INSTITUTES.
>> YES, WE CAN PUT THAT LANGUAGE
IN THERE TO ENCOURAGE THAT.
>> GREAT, THANK YOU.
>> SO ARE THERE QUESTIONS FROM
OTHER BOARD MEMBERS?
>> YEAH.
>> SO I'M WONDERING HOW WE WALK
THE LINE BETWEEN FUNDING
RESEARCH FOR BIO-INFORMATICS
TRANSLATIONAL INFORMATICS AND SO
ON AND BIOLOGICAL AND
TRANSLATIONAL RESEARCH.
YOU KNOW IT'S 1 THING TO BUILD
BLAST, IT'S ANOTHER THING TO USE
BLAST TO CURE CANCER AND YOU
KNOW I THINK THAT'S A WORTHY
GOAL BUT THE NLM HAS A VERY
LIMITED BUDGET AND THE NCI ISN'T
GOING TO FUND -- SPEND A LOT OF
TIME FUNDING INFORMATICS
RESEARCH WHEN THERE ARE
INFORMATICS RESEARCH TOOLS THAT
CAN BE APPLIED TO CANCER
RESEARCH SO I THINK WE HAVE TO
BE CAREFUL NOT TO FUND THINGS
THAT ARE EITHER REALLY PURELY
USE OF EXISTING TOOLS TO CONDUCT
BIOMEDICAL RESEARCH OR CLEVERLY
DISGUISED BIOMEDICAL RESEARCH
WHETHER IT'S WELL, WE'RE GOING
TO BUILD THIS TOOL AND WE WILL
SPEND A HUNDRED THOUSAND DOLLARS
BUILDING THIS TOOL AND THEN
SPEND A MILLION DOLLARS TESTING
IT IN A CONTROLLED CLINICAL
TRIAL TO CURE CANCER, NOT TO
PICK ON NCI, BUT YOU GET MY
POINT.
SO HOW DO WE MAKE SURE THAT WE
WALK THAT LINE?
AS IT IS NOW, I OFTEN SEE GRANTS
THAT ARE FUNDED BY NLM THAT LOOK
TO ME AND I'M NOT A BIOINFORMAT
CYST PURPOSE TO LOOK TO BE MORE
ABOUT STUDYING A DISEASE MORE
THAN STUDYING A NEW METHOD FOR
STUDYING A DISEASE?
>> YEAH, DEFINITELY THE FOCUS IS
GOING TO BE ON THE PRODUCTION
BUT OBVIOUSLY THE USE HAS TO BE
REALLY CONSIDERED.
LIKE THE CORE OF THE GRANT WOULD
NOT BE ABOUT DOING LIKE THE
APPLICATION --
>> YEAH AND YOUR LIST OF
EXAMPLES WAS A GOOD 1 SO I
LOOKAD THAT AND I SAID YEAH,
THAT'S WHAT IT SHOULD LOOK LIKE,
BUT I THINK IT BEARS REINFORCING
WITH REVIEWERS, THAT THAT'S --
THOSE ARE THE KINDS OF EXAMPLES
AND MAYBE HAVING COUNTER
EXAMPLES TO SAY THESE ARE THE
KINDS OF THINGS THAT WE WILL
SEND TO OTHER INSTITUTES AND
TELL THEM TO CONSIDER THEM
BECAUSE IT'S REALLY IN THEIR
PERVIEW.
SO IT MIGHT BE WORTH HAVING
EXPLICIT EXAMPLES OF THAT.
AND THE WORKSHOP, THE RETREAT
WHATEVER IN SEPTEMBER MIGHT BE A
GOOD TIME TO EXPLORE THAT.
>> YES, YES, THANK YOU.
THAT'S A GOOD SUGGESTION, TOO.
>> ANY OTHER QUESTIONS?
,
>> I WAS CURIOUS ABOUT 1 THING,
YOU MENTIONED THE
BIO-INFORMATICS HAVE A SLITLY
LOWER SUCCESS RATE AND I WAS
WONDERING THERE WAS AN ANALYSIS
AS TO WHY THAT MIGHT BE?
>> IT WASN'T TERRIBLY LORER IT
WAS LIKE 10 VERSUS 12 OR
SOMETHING LIKE THAT, BUT IT
VARIES FROM YEAR TO YEAR, SO IT
WASN'T ANYTHING SIGNIFICANT.
>> OH, OKAY, OKAY.
>> I WILL JUST GO AHEAD AND
REITERATE WHAT DR. QUITACK SAID
ABOUT THE INTERDISCIPLINARY
ASPECTS OF IT, I WOULD REALLY
LIKE TO HEAR THAT AS WELL AS
GENERALIZATION AND APPLICABLE.
I RECOGNIZE THERE HAVE BEEN A
LOT OF CONSOLIDATION OF THE
CENTERS AND EN--STRATEGIESITUTE
BUT AT THE SAME TIME WHEN I
THINK ABOUT THE AMOUNT OF CROSS
POLLINATION AND CROWD SOURCE
THAGOREAN CAN TAKE PLACE WITH
THESE CONSOLIDATIONS SO I'M
HOPING THAT COMES INTO FRUITION,
SHOULD THESE CONSOLIDATIONS TAKE
PLACE, AND I LOOK TO WHAT
DR. SOMINO SAID ABOUT SENDING
THINGS ACROSS INSTITUTESSA WELL.
I BELIEVE WE WILL HAVE STILL
THAT BODY OF THESE 27 CENTERS
AND INSTITUTES AND THAT MIND --
THAT WONDERFUL MINDS UP THERE
THAT SOMEHOW SOMEWAY WE CAN
REALLY TALK TO EACH OTHER MORE
AND REALLY UNDERSTAND THAT THE
HUMAN BODY IS A BODY, NOT JUST
SYSTEMS, RIGHT?
SO AS WE CAN BEGIN TO THINK
ABOUT THIS REORG, ALSO AS MORE
WHOLISTIC RESEARCH AS WELL.
>> YEAH, WELL, AS THE POLICIES
ARE ADOPTED AND NEW DATA SHARING
AND STANDARDIZATION, WE WOULD
TRY TO YOU KNOW ENDEAVOR TO HAVE
THIS WHOLE FUNDING OPPORTUNITY
BE COMPATIBLE WITHIN IT, IF
THERE WAS A NEW NIH, THAT WOULD
PROBABLY GET TYPED ON TO THE
NOFO, WE WOULD ABSOLUTELY WANT
IT TO BE COMPATIBILITY BUT JUST
ESTABLISHING THAT TYPE OF
CENTRALIZATION IS BEYOND THE
SCOPE, IT'S PARTICULAR TYPE OF
FUNDING.
>> SO ANYONE ELSE HAVE A
QUESTION?
>> NOT A QUESTION, JUST A QUICK
COMMENT, THANK YOU FOR YOUR
PRESENTATION ON THIS NOFO.
SO I JUST WANT TO COMMENT ON
ANN'S SYSTEM, THERE IS A DATA
SHARING PLAN THAT IS EXPECTED OF
ALL APPLICANTS AND SO WE ARE
PLACING A HEAVY EMPHASIS ON HOW
ARE THESE TOOLS GOING TO BE
SHARED AND THAT IS SOMETHING
WE'VE BEEN EVALUATING FOR THE
LAST 2 YEARS WITHIN THE
DIVISION, TO INSURE THAT THAT
THE TOOLS WE FUND ARE ADOPTED
AND DISSEMINATED AND IN TERMS OF
RASMUS, IN TERMS OF THE
RESOURCES, YOU KNOW THIS PARENT
ANNOUNCEMENT IS A RESEARCH
ANNOUNCEMENT AND YOU KNOW WE ARE
WELL AWARE THAT THERE ARE
RESOURCES NEEDED TO SUSTAIN
TOOLS, AND TO UPDATE TOOLS, AND
I DO THINK THAT THAT'S SOMETHING
ON THE HORIZON THAT NLM AND NIH
HAS TO HAVE A DISCUSSION ON.
ALTHOUGH THESE ARE FOCUSED MORE
ON RESEARCH GRANTS, THERE'S THE
INNOVATION COMPONENT TO THE
RESEARCH THAT'S EVALUATED WE
HAVE TO CONTINUE TO INSURE THAT
FUND SUGGEST PROVIDED TO UPDATE
TOOLS, IF NOT THOSE TOOLS BECOME
OBSOLETE AND OUTDATED AND 1 LAST
COMMENT TO JIM, WHEN WE EVALUATE
THESE GRANTS, YOU KNOW IT IS
EVALUATED ON THE TOOL, THE
INNOVATION, THE METHODOLOGY, AND
I THINK AS WE MOVE FORWARD INTO
THIS NEW FUNDING PROCESS, IN
FISCAL YEAR 26, YOU KNOW WE
WELCOME THE BOARD'S COMMENT, YOU
KNOW IF YOU THINK THAT A TOOL IS
BEING DEVELOPED FOR MORE OF A
DOWN STREAM PROJECT THAT IS NOT
REALLY ALIGNED WITH NLM'S VISION
AND MISSION, WE DEFINITELY WANT
TO HEAR FROM THE BOARD ON THOSE
APPLICATIONS.
BECAUSE YOU KNOW THE FOCUS OF
THAT RO-1, IS REALLY ON
DEVELOPING NEW AND INNOVATIVE
METHODS AND TOOLS AND APPROACHES
THAT ARE GENERALIZABLE.
THAT'S ALL I WANT TO SAY, THANKS
KATHRYN.
>> SO THANK YOU AGAIN, KATHRYN,
IT WAS A GOOD DISCUSSION.
WE WILL MOVE TO
DR. GATHAM-REDDY, AND HE WILL
PRESENT A CONCEPT CLEARANCE FOR
CLINICAL INFORMATICS RESEARCH
PROGRAM.
>> LOLA BEFORE WE GO THERE WE
NEED TO HAVE A MOTION ON THIS
CONCEPT, WE HAVE TO APPROVE THIS
CONCEPT.
>> OH, RIGHT.
SO THERE'S A VOTE NEEDED TO --
>> I MOVE FOR APPROVAL?
>> SECOND?
>> I'LL SECOND.
>> ALL IN FAVOR, RAISE YOUR
HANDS VISIBLE?
>> OKAY, LOOKS LIKE IT'S
APPROVED.
AND SO WE WILL MOVE ON TO
CONCEPT CLEARANCE FOR RESEARCH
GRANTS AND CLINICAL INFORMATICS
PRESENTED BY DR. BOTHAM-REDDY.
>> THANK YOU.
LET ME SHARE MY SCREEN HERE.
CAN EVERYONE SEE MY SCREEN?
>> YES.
>> SO, I'LL BE PRESENTING HERE
THE CONCEPT CLEARANCE FOR
RESEARCH PROGRAM IN CLINICAL
INFORMATICS, I AM A PROGRAM
OFFICER ALONG WITH DR. SARAH NG
UYEN, IN EXTRA MIEWR PROGRAMS.
BY WAY OF BACKGROUND ADVANCES IN
TECHNOLOGY AND DATA ANALYTICS
HAVE BROUGHT US CLOSER TO THE
FUTURE ENVISIONED BY THE
2017-2027 NLM STRATEGIC PLAN AD
SPECIFICALLY GOAL 1 TO ADVANCE
DISCOVERY THROUGH DATA DRIIVE
RESEARCH, ADVANCING CLINICAL
INFORMATIC SYSTEM CRITICAL TO
TRANSFORMING HEALTH DATA INTO
ACTIONABLE KNOWLEDGE THAT CAN
DRIVE BETTER OUTCOMES IN CARE
AND POPULATION HEALTH.
AS A LEADER IN INFORMATION
SCIENCES, NLM WILL CONTINUE TO
PROVIDE DIRECTION FOR BUILDING
CLINICAL INFORMATIC IT IS IN
DORPHY WITH COLLABORATION,
INSTITUTES AND CENTERS.
A PORTFOLIO ANALYSIS OF CLINICAL
INFORMATICS SHOWS THAT NLM'S
CURRENT RESEARCH PORTFOLIO
RANGES FROM ARTIFICIAL
INTELLIGENCE DECISION SUPPORT,
MEDICAL LANGUAGE PROCESSING,
HIGH SPEED ACCESS TO BIOMEDICAL
INFORMATION AMALSIS, USAGE OF
IMAGING DATA AND LARGE SCALE
ANALYSIS OF CLINICAL AND
ADMINISTRATIVE DATA TO IMPROVE
PATIENT OUTCOMES IN FISCAL YEAR
2024, AND NLM RECEIVED 58
APPLICATIONS FOR RESEARCH
PROGECS IN CLINICAL INFORMATICS,
CORRESPONDING TO 25% OF ALL OUT
PATIENTS RECEIVED.
SEVEN OF THOSE APPLICATIONS WERE
AWARDED INDICATING SUCCESS RATE
OF 12%.
SO THE GOAL OF THIS NOFO IS
REALLY TO ADVANCE THE
DEVELOPMENT OF NOVEL INFORMATICS
APPROACHES AND TOOLS THAT CAN
HELP CLINICIANS AND INDIVIDUALS
UNDERSTAND AND IMPROVE THEIR
OVERALL HEALTH.
THE OBLIGATIONS YECTIVES THEN IS
REALLY FOCUSED ON DISEASE
DIAGNOSTIC APPROACHES TO FOSTER
DATA DRIVEN DISCOVERY AS WELL AS
DOMAIN DEPENDENT SCALABLE,
REUSABLE OR REPRODUCE ABLE
APPROACH FOR DISCOVERY, AND
HEALTH RELATED DIGITAL OBJECTS
TO TRANSFORM INTO KNOWLEDGE AND
HEALTH.
AND AS RESULT WE WANT TO PROMOTE
CLINICAL INFORMATICS TO
TRANSFORM HEALTHCARE TO IMPROVE
PATIENT CARE, STRENGTHEN
CLINICIAN PATIENT RELATIONSHIPS,
AND PROMOTE PATIENT CARE THAT IS
SAFE, EFFICIENT, TIMELY AND
EQUITABLE.
SOME EXAMPLES OF PROJECTS BUT
NOT INCLUSIVE WOULD BE
DEVELOPING NEW INNOVATIVE
APPROACHES TO HARMONIZING
DIVERSE, CLINICALLY RELEVANT
DATA STREAMS, EXPLORING ADVANCED
TECHNIQUES THAT,A LOW FOR
SECONDARY USE TO APPROVE
CLINICAL DECISION SUPPORT AND
OUTCOMES, RESEARCH ON EHR
USABILITY, INTEROPERABILITY AND
TOOLS TO STREAMLINE CLINICAL
DOCUMENTATION, REDUCE CLINICAL
BURDEN, DEVELOP AI TOOLS AND
METHODS WITH THE FOCUS ON
BENEFITS, TO PATIENTS AND HEALTH
SYSTEMS, BUILDING CLINICAL
DECISION SUPPORT AND
PATIENT-CENTRIC TOOLS, TOOLS AND
METHODS REALLY TO ASSESS
INFORMATION AND KNOWLEDGE NEEDS
AND HEALTHCARE PROFESSIONALS AND
PATIENT'S AUTOMATE
ADMINISTRATIVE PROCESSES, REDUCE
WORKFORCE BURDEN AND BY WAY OF
MECHANISM AGAIN, IT IS GOING TO
BE AN RO-1, IT'S ANTICIPATED
THAT NLM WILL PROVIDE $250,000
IN DIRECT COSTS PER YEAR FOR A
MAXIMUM OF 4 YEARS, THE SUCCESS
OF THIS FUNDING OPPORTUNITY WILL
BE EVALUATED BASED ON
PUBLICATIONS RESULTING FROM
FUNDED PROJECTS, CITATIONS,
REPRESENTATION OF FUNDED
RESEARCH AND CONFERENCES, NEWS
ARTICLES AND SUCCESSFUL USE OF
THE RESULTING RESEARCH PRODUCTS
BY THE WIDER RESEARCH COMMUNITY.
WITH THAT BEING SAID, PLEASE IF
ANYONE HAS ANY QUESTIONS PLEASE
DO ASK.
>> SO THANK YOU SO MUCH FOR THAT
PRESENTATION AND WE WILL HAVE
CHRIS FOREST, MITCH K ATZ HAD TO
LEAVE EARLY, WE WILL HAVE CHRIS
LEAD THE DISCUSSION AND OTHER
BOARD MEMBERS CHIME?
>> HAPPY TO KICK IT OFF.
DR. REDDY, THANKS FOR THAT.
ONE OF THE COMMENTS I WANT TO
MAKE IS JUST HOW IMPORTANT THE
NATIONAL LIBRARY OF MEDICINE
CLINICAL INFORMATICS PRIORITIES
ARE, THEY WILL FUND A CERTAIN
NUMBER OF GRANTS, BUT THEY ALSO
PERCOLATE THROUGHOUT OTHER
PROJECTS THAT ARE FUNDED UNDER
OTHER MECHANISMS TO THE NIH.
I ALSO SEE JUNIOR INVESTIGATORS
LOOKING AT WHAT THE NLM
PRIORITIES ARE SO I NOT TO POINT
OUT THEY HAVE WIDE SPREAD IMPACT
SO THE MORE WE CAN SORT OF
CONVEY IN YOUR BULLETS, WHAT
THOSE MEAN, THE BETTER I THINK
FOR THE INFORMATICS COMMUNITY.
THE SECOND POINT I WANT TO MAKE
IS, IT'S REALLY -- KEVIN
JOHNSON'S VIDEO THAT WAS SHOWN
EARLIER, KEVIN'S A COLLEAGUE
HERE AT PEIN, N, IT'S AMAZING
THAT KIND OF WORK.
SO NOW HE'S THINKING DOWN STREAM
YEARS IN ADVANCE AND THAT'S WHY
I WANT TO GET TO EVERY HEALTH
SYSTEM I KNOW, ALL THE BIG
HEALTH SYSTEMS NOW ARE INVESTING
WITH THE BIG IT COMPANIES AND
NEXT GENERATION AI PREDICTIVE
ANALYTICS AND I'M I'M WONDERING
HOW THIS CLINICAL INFORMATICS
STRATEGIC SET OF PRIORITIES WILL
SUPPORT THAT OR NOT SUPPORT
THAT.
AND I HAVE A FOLLOW UP QUESTION
FOR THAT.
>> YEAH, WELL, CERTAINLY SUPPORT
THAT AND I THINK YOU'VE BROUGHT
UP AN IMPORTANT POINT ABOUT AI,
AND I THINK 1 OF THE OVERARCHING
GOALS OF AI IN HEALTHCARE REALLY
SHOULD BE HOW DO THESE TOOLS AND
METHODS AND AI BASED TECHNIQUES,
HELP CLINICIANS OR HELP CLINICAL
STAFF, IMPROVE WORK FLOWS OR
MAKE BETTER DECISIONS AND I
THINK SOME OF THE CHALLENGES WE
SEE IN THIS SPACE REALLY WOULD
CENTER AROUND DATA MANAGEMENT
AND DATA QUALITY AND GOVERNANCE
AND ALL THINGS YOU HAVE TO DO TO
ALLOW AI TO WORK EFFECTIVELY.
AND I THINK THAT'S 1 OF THE
THINGS WITH CLINICAL INFORMATIC
SYSTEM VERY IMPORTANT IS HOW DO
YOU SET THAT CONTEXT AND
EVALUATE GRANTS AND
TECHNOLOGIES, WITHIN THIS SPACE.
>> YEAH, AND THAT'S MY FOLLOW UP
POINT, YOU KNOW I THINK THAT THE
EHR DATA, OTHER KINDS OF
CLINICAL INFORMATION SYSTEMS,
STILL NEED MORE METHODS
DEVELOPED TO CREATE ANALYTIC
DATA SETS THAT ARE FIT FOR
PURPOSE, BOTH FOR AI ALGORITHMS
AS WELL AS FOR RESEARCH AND SO I
WOULD LOOK TO SEE SOME THOUGHT
TO HOW WE CAN STIMULATE THOSE
KINDS OF NEW KNOWLEDGE
GENERATION FIT FOR PURPOSE TYPE
APPLICATIONS BECAUSE THEY WILL
BE UNIVERSAL.
THEY COULD HELP A LOT OF
RESEARCH.
SORT OF LIKE RESEARCH ON
RESEARCH AND THE OTHER PIECE
HERE IS THAT THE AMOUNT OF DATA
THAT IS NOW BEING GENERATED
CLINICALLY WITH WHOLE GENOME
ANALYSIS NOW BEING DONE IN SO
MANY PATIENTS IS GOING TO LEAD
TO MULTIMODAL PHENOTYPING AS
KIND OF A MATTER OF ROUTINE IN
RESEARCH, SO INCORPORATING THAT,
ALSO FEELS TO ME LIKE IT WOULD
BE A PRIORITY OF THE FUTURE.
>> ABSOLUTELY AND I THINK SOME
OF WHAT YOU MIGHT BE SAYING IS
THE PRESUMED BENEFITS OF
TECHNOLOGY AND WHEN WE USE AI.
YOU KNOW I THINK THAT 1 OF THE
THINGS WE'RE SEEING AS WE MOVE
FORWARD WITH MORE TECHNOLOGY, OR
MORE DATA IS, THERE ARE THESE
SORTS OF ADDITIONAL QUESTIONS
AROUND SAY FIRE READINESS,
RIGHT?
I THINK MOST PLACES JUST HAVE
ENOUGH TO MEET MEANINGFUL USE
STANDARDS BUT IF YOU WERE TO USE
PAST THAT LEVEL, HOW DO YOU
REALLY CREATE THAT
DIFFERENTIATION.
SO, I THINK THESE ARE EXCELLENT
QUESTIONS AND WE'VE HAD
DIALOGUES LIKE THIS INTERNALLY
WITHIN THE PROGRAMMATIC STAFF.
>> THAT'S GREAT, THAT'S ALL I
HAVE TO SAY.
THANK YOU VERY MUCH.
>> THANK YOU.
>> OKAY, SO WE WILL OPEN IT UP
FOR WIDER DISCUSSION AND
ACTUALLY I HAD A QUESTION ABOUT
WHETHER THIS MECHANISM WOULD BE
THE RIGHT PLACE FOR SOME
RANDOMIZED TRIALS OF AI-BASED
DECISION SUPPORT, SO, THERE'S
THIS -- I USE AI IN MY WORK AND
I AM A BIG MACHINE LEARNING
PROPONENT BUT THERE'S THIS
INHERENT ASSUMPTION THAT IT WILL
MAKE THINGS BETTER AND NOT AS
MANY STUDIES OF WHETHER IT DOES
MAKE THINGS BETTER IN A
RANDOMIZED WAY AND IS THAT A
GOAL OF THIS?
I MEAN WOULD THAT FIT WITHIN
THIS MECHANISM OR WOULD THAT FIT
SOMEWHERE ELSE AND IS ANYONE
LOOKING AT THAT MORE BROADLY.
>> SO THIS IS A FANTASTIC
QUESTION.
I THINK THIS SORT OF MAY GO BACK
TO SOME EARLIER POINTS ABOUT
PRODUCT DEVELOPMENT, TOO.
YOU KNOW WHAT IS THE LIFE CYCLE
OF WHAT NLM SPECIFICALLY
SUPPORTS, IS IT, YOU KNOW IF WE
LOOK AT SOME -- LET'S SAY DRAW
AN ANALOGY TO DRUG DEVELOPMENT,
THERE'S BENCH SIDE AND THEN WE
GO TO CLINIC AND MAYBE UP TO
THAT PHASE 3 CLINICAL TRIAL
PHASE SO LET'S CALL THAT SCIENCE
AND PRACTICE, AND THEN THERE'S
DELIVERY.
YOU KNOW SHOULD NLM REALLY FOCUS
ON SCIENCE AND PRACTICE?
VERSUS DELIVERY IN THE HEALTH
SYSTEM BECAUSE THAT INVOLVES
MANY MORE FACTORS AND YOU KNOW
ANECDOTALLY I COULD ALSO SEE IF
WE GO TO THE DELIVERY LEVEL,
AHRQ AS AN ORGANIZATION HAS PUT
OUT A NUMBER OF NOFOs AROUND
VOLUME BASED METRICS AND THE
LIKE, SO, I THINK THESE ARE
IMPORTANT QUESTIONS, AND I HOPE
I ADDRESSED YOUR QUESTION, BUT,
AS I WOULD VISUALIZE IT, YOU
KNOW, THESE ARE FANTASTIC
QUESTIONS.
>> OTHER QUESTIONS FROM BOARD
MEMBERS?
>> WELL, THANK YOU SO MUCH, A
LOT OF FOOD FOR THOUGHT AND I
BELIEVE THERE'S A VOTE NEEDED
FOR THIS CONCEPT CLEARANCE AS
WELL.
SO DO WE HAVE A MOTION?
>> MOTION TO APPROVE.
>> OKAY, WE HAVE A MOTION FROM
CHRIS, SECOND FROM JIM SAMIRINO,
AND ALL IN FAVOR JUST PLEASE
RAISE YOUR HAND.
OKAY.
SO MOVED.
>> THANK YOU.
>> NEXT UP WE HAVE
DR. CLAYTON-BING HAM WHO IS A
PROGRAM OFFICER FROM AGAIN, THE
NLM'S DIVISION OF EXTRAMURAL
PROGRAMS AND DIRECTOR OF THE T15
TRAINING PROGRAM WILL PROVIDE AN
UPDATE AND OVERVIEW OF THE NLM
UNIVERSITY BASED BIOINFORMATTICS
AND DATA RESEARCH TRAINING
PROGRAM.
>> AWESOME.
THANK YOU VERY MUCH.
YEAH, I'M A PROGRAM OFFICER AND
WITH THE BUSINESS PORTFOLIO AND
I ALSO DIRECT THE T15 DATA
SCIENCE AND TRAINING PROGRAM AND
TODAY'S PRESENTATION WILL BE
FOCUSED ON PROVIDING A SNAPSHOT
OF THE T15 PROGRAM.
LET'S ADVANCE.
SO FOR OVER 40 YEARS, NLM
SUPPORTED PREMIER BIOMEDICAL
INFORMATICS AND DATA SCIENCE
TRAINING PROGRAMS ACROSS THE
COUNTRY.
THIS PROGRAM HAS A RICH HISTORY
THAT IS DEEPLY INTEGRATED WITH
NLM'S OWN EVOLUTION INTO AN
INSTITUTE THAT REALLY DRIVES
TECHNICAL DATA LITERACY AND
SUPPORTS THE DEVELOPMENT OF
INNOVATIVE TOOLS AND METHODS FOR
TURNING DATA INTO KNOWLEDGE AND
REALLY ELEVATING THE RIGOR OF
DATA DRIVEN SCIENCE AND
HEALTHCARE.
I PERSONALLY LIKE TO DESCRIBE
THE T15 BY SAYING THAT IF NLM
WERE A 3-LEGGED STOOL, THE T15
IS 1 OF THOSE LEGS.
GRANTEE INSTITUTIONS SUPPORT
NLM'S GOALS BY PROVIDING
COMPREHENSIVE CURRICULA AND
PROFESSIONAL DEVELOPMENT TO
TRAINEES WITH THE AIM OF
BUILDING A ROBUST PIPELINE OF
DATA LITERATE SCIENTISTS THAT
HAVE READY SKILLS TO TOWARD THE
LEADINGA EDGE OF A LOT OF
DIFFERENT SCIENTIFIC DOMAINS AND
IN HEALTHCARE.
THE CURRENT ITERATION OF THE
PROGRAM JUST ENTERED ITS FOURTH
YEAR AND COMPRISES 5 YEAR AWARDS
TO SUPPORT TRAINEE PREPAREDNESS
OR IMPACTFUL CAREERS IN
BIOMEDICAL INFORMATICS AND DATA
SCIENCE.
THE CURRENT COHORT INCLUDES 18
AND PUBLIC PRIVATE INSTITUTIONS
THAT ARE BROADLY DISTRIBUTED
ACROSS THE COUNTRY.
THERE ARE APPROXIMATELY 163
CURRENT TRAINEE SLOTS AND THOSE
HAVE A RATIO OF A ABOUT 3-1
PREDOCTORAL STUDENTIAL TO POST
DOCTORAL APPOINTUTES.
T15 TRAINEES UNDERGO VERY
COMPETITIVE SELECTION AND
THEY'RE OFTEN DOUBLY CHOSEN FROM
WITHIN A LARGER INSTITUTIONAL
TRAINING PROGRAM IN WHICH THE
T15 IS AN EMBEDDED COMPONENT.
SOME PROGRAMS SELECT T15
TRAINEES ON MATRICULATION AND
OTHERS RESERVE SLOTS FOR
TRAINEES THAT HAVE COMPLETED
SOME PORTION OF THEIR GRADUATE
TRAINING AND THERE ARE PROS AND
CONS TO BOTH OF THOSE APPROACHS
AND IT'S INTERESTING TO SEE HOW
THAT PANS OUT IN THE REAL
MATURITY LEVEL OF TRAINEES OVER
THE TIME -- OVER THE DURATION OF
THEIR AAPPROPRIATE TO THE T15.
>> SO OVER THE LEFT OF THE
PROGRAM, THE T15 HAS PRODUCED
OVER 1700 BIOMEDICAL
INFORMATICIANS AND DATA
SCIENTISTS AND A LOT OF THOSE
HAVE GONE ON TO VERY HIGHLY
PRODUCTIVE AND IMPACTFUL CAREERS
IN INDUSTRY, ACADEMIA, AND
GOVERNMENT.
AND I THINK THAT THERE'S BEEN
SOMETHING OF A RECKONING HERE IN
RECENT YEARS.
THE SKILLS PROVIDED BY THESE
PROGRAMS ARE EXPERIENCING
DISPROPORTIONATE DEMAND IN
INDUSTRY VERSUS ACADEMIA, ALSO
OR PERHAPS IN SPITE OF LIMITED
GROWTH AND PROGRAM FUNDING AND
TRAINING LOTS, TRAINEES EXHIBIT
REALLY PROMISING GROWTH AND
PRODUCTIVITY, VERY STRONG
INCREASES IN PUBLICATIONS AND
RESPECTED AND HIGH IMPACT
JOURNALS, AND YOU KNOW, REALLY
THE T15 IS ASSOCIATED WITH
OVER200 PUBLICATIONS A YEAR AND
A REALLY LARGE PROPORTION OF
THOSE FEATURE AN ACTIVE TRAINEE
AS FIRST AUTHOR.
IT'S WORTH MENTIONING HERE, THAT
THE -- THAT NIH HAS A
POLARIZEDEE THAT ALL
PUBLICATIONS ASSOCIATE WIDE
SALARY OR STIPEND SUPPORT MUST
CITE THE NIH AWARD EACH IF THE
STUDY OR PUBLICATION IS
PRIMARILY SUPPORTED OR
ASSOCIATED WITH OTHER SOURCES OF
SUPPORT.
SO WHILE THIS CAN MAKE FOR A
LITTLE BIT OF A CHALLENGING
NARRATIVE FOR THE T15 IN TERMS
OF YOU KNOW MEASURING ACUTE
SCIENTIFIC IMPACT, IT'S REALLY
VALUABLE TO RECOGNIZE THE
CONTRIBUTIONS OF THE T15 TO
PROJECTS THAT ARE SUPPORTED
THROUGH OTHER GRANT MECHANISMS.
I REGULARLY REMIND TRAINING
DIRECTORS THAT WHENEVER T15
TRAINEES HAVE A SIGNIFICANT
ACCOMPLISHMENT, THAT THEY SHOULD
OF COURSE, DOCUMENT IT, AND PUT
IT IN ANNUAL REPORTING BUT I
LIKE THEM TO SEND ME A DIRECT
MESSAGE AND TELL ME THAT
SOMETHING WILL HAPPEN SO I CAN
BRAG ABOUT IT IF THE OCCASION
ARISES.
THESE ARE A SMALL COLLECTION OF
SOME OF THE MOST HIGHLY CITED
T15 TRAINEE-LED PRODUCTS FROM
THE LAST 3 YEARS.
YOU CAN SEE HOW BROAD THE IMPACT
REALLY IS ACROSS SCIENCE, YOU
KNOW JUST LOOKING AT THE
JOURNALS THAT THEY'RE PUBLISHING
IN, BUT IF YOU LOOK AT THE
TITLES, THEY'RE VERY BROAD, BUT
WHAT IS CERTAINLY TRUE ABOUT
THESE, AND THIS SLIDE ORIGE
NAWILLLY WAS DESIGNED TO INCLUDE
A TOPIC, WORD CLOUD, MADE CLEAR
THAT DATA AND DATA LIFE CYCLE,
AND THE DATA LIFE CYCLE REALLY
LIESA THE CENTER OF WHAT T15
TRAINEES ARE DOING.
THE POINT BEING THAT WHETHER IT
IS BETTER STRATEGIES FOR
ACQUISITION, CURATION,
MANAGEMENT, SAFETY, SECURITY,
MODELING, YOU KNOW ON ALL THE
WAY THROUGH TO DISSEMINATION OF
THESE PRODUCTS AND DATA, THE NLM
T15 HAS PLAYED A REALLY STRONG
ROLE IN NOD ONLY PRODUCING THIS
SCIENCE BUT BUILDING A ROBUST
PIPELINE OF EXPERTS WHO WILL
CONTINUE THIS WORK INTO THEIR
FUTURE CAREERS.
SO AFTER CAREFUL COALITION OF
APPLICATIONS, APPROXIMATELY 54%
OF DE15 ALUMNI HOLD TRAINING
RELEVANT POSITIONS IN RESEARCH
INSTITUTIONS.
TWENTY-SEVEN% HELD TRAINING
RELEVANT POSITIONS IN INDUSTRY
WITH 2% IN GOVERNMENT AND AN
ADDITIONAL 16% UNKNOWN OR
UNRELATED.
RESPECTABLE PROPORTION OF THOSE
WORKING AT RESEARCH INSTITUTIONS
WENT ON TO BE A PI OR CO-I, ON
SUBSEQUENT RESEARCH FOR CAREER
GRANTS AND IT'S IMPORTANT TO
NOTE THAT THOSE WORKING IN
INDUSTRY ARE OFTEN FOUND IN HIGH
IMPACT POSITIONS OF REALLY
NOTABLE AND PROMINENT FIRMS IN
ROLES WHERE THEY DIRECTLY
UTILIZE THE SKILLS AND
EXPERIENCE THAT THEY GAINED IN
THE T15 PROGRAM.
IT'S CLEAR FROM THESE DATA THAT
TRAINEES ARE ON AVERAGE VERY
WELL EQUIPPED TO CLIMB CAREER
LADDERS IN DIVERSE PROFESSIONAL
ENVIRONMENTS.
SO, WHILE THE ACHIEVEMENTS OF
THE T15 ARE ENCOURAGING, THE
PROGRAM IS CERTAINLY FACED WITH
MEANINGFUL CHALLENGES, BOTH
PRESCRIBING LENIENT AND GOING ON
INTO THE FUTURE.
THE PLOT ON THE LEFT HERE SHOWS
THE NUMBER OF PREDOCTORAL AND
POST DOCTORAL TRAINEES THAT HAVE
BEEN SUPPORTED SINCE 2006.
THE MIDDLE PLOT SHOWS THE TOTAL
NUMBER OF T15 AWARDS MADE IN
EACH OF THE PAST 3 PROGRAM
ITERATIONS, AND THE PLOT ON THE
RIGHT SHOWS THE AVERAGE -- THE
AVERAGE COST SUPPORT PER TRAINEE
SINCE 2012 IN REAL $2024.
SO THE DECREASING NUMBER OF
APPOINTMENTS, INFLATION RELATED
DIMINISHING SUPPORT PER TRAINEE
AND RISING INSTITUTIONAL COSTS
AND INCLUDING STIPENDS AND FNA,
REALLY PRESENT CHALLENGES THAT
LIMIT CONTINUED GROWTH OF
PROGRAM IMPACT.
NOTABLY, THE VALUE OF THIS
TRAINEES TO INDUSTRY, IS VERY
HIGH AND OPPORTUNITY COSTS
ASSOCIATE WIDE CONTINUING
TRAINING VERSUS TAKING HIGH
PAYING INDUSTRY POSITIONS MAKES
RECRUITMENT AND RETENTION OF
POST DOCS, VERY DIFFICULT IN
PARTICULAR AND PARTICULARLY
POINTING OUT THE CHALLENGES AND
RECRUITING AND RETAINING POST
DOCS IN THESE PROGRAMS.
AND THIS IS REFLECTED IN THE
RELATIVELY HIGH CAREER PLACEMENT
RATES AND FREQUENT REQUESTS FROM
PIs TO CONVERT POST DOC SLOTS
TO PREDOC SLOTS OVER THE PAST
FEW YEARS OF THE PROGRAM.
THAT SAID, YOU KNOW DESPITE
THESE CHALLENGES, TRAINEES HAVE
MORE OPPORTUNITY NOW, THAN EVER
BEFORE TO PURSUE REALLY
IMPACTFUL AND OFTEN LUCRATIVE
CAREERS IN BIO-INFORMATICS AND
DATA SCIENCE.
TO ADD TO THIS A BIT, THERE HAVE
BEEN RECENT TROUBLES IN BIOTECH,
HEALTHCARE, FARM AND RELATED
SECTORS RELATED TO RECRUITMENT
RETENTION AND THAT'S SOMETHING I
WILL HAVE TO KEEP AN EYE ON JUST
TO SEE IF THIS TREND CONTINUES
AND BECOMES SOMETHING WE NEED TO
ADAPT TO STRATEGICALLY.
ONE NUANCED INSIGHT THAT'S WORTH
HIGHLIGHTING IS THAT THE T15
PROGRAM CREATING ACADEMIC VALUE,
WELL BEYOND THE NLM RESEARCH
COMMUNITY.
THIS IS PARENT WHEN YOU TAKE A
LOOK AT THE SHIFT IN THE
DISTRIBUTION OF FUNDING SOURCES
OBTAINED BY T15 ALUMNI AND THE
TYPES OF JOURNALS THAT THEY
PUBLISH IN ONCE THEY ENTER THE
WORKFORCE.
OT LEFT YOU CAN SEE IN ADDITION,
THEY HAVE 1 MAJOR GRANTS FROM N
IGMS AND OTHERS AND ON THE RIGHT
YOU SEE THE EMERGENCE MUCH
DISEASE JOURNALS SUCH AS BLOOD,
VIROLOGY, CANCER RESEARCH AS
TARGET JOURNALS FOR T15 ALUMNI.
REALLY THIS IS IN LINE WITH THE
GOALS OF NLM WITH RESPECT TO
TRAINING AND INFORMATICS AND
DATA SCIENCE.
TRAINEES TAKE THE VALUABLE
SKILLS THAT I GAIN AND APPLY IT
TO A BROAD ARRAY OF PROBLEMS
INCLUDING DISEASE SPECIFIC
PROBLEM IN ADDITION TO MORE CORE
METHODS AND TOOL CENTRIC EFFORTS
THAT NLM FOCUSES ON.
THE MAIN TAKE AWAY FROM THIS IS
THAT THE NLM T15 CREATES CROSS
CUTTING VALUE TO THE ENTIRE NIH
ECOSYSTEM AND THE COMMUNITIES IT
SERVES AND I RAISE THIS AS A
POINT BECAUSE I HAVE A PERSONAL
BELIEF THAT THE NLM T15 PROBE
PROGRAM CAN AND SHOULD HAVE
SHARED INTEREST ACROSS THE NIH
ECOSYSTEM AND THAT'S AN APPROACH
THAT HAS BEEN CONSIDERED IN THE
PAST.
WE'VE HAD NIAID PARTICIPATE IN
THE T15 PROGRAM AND THAT'S A
MODEL I WOULD LIKE TO SEE
CONTINUE.
WITH THAT WE HAVE TIME FOR
QUESTIONS.
I DID ANTICIPATE A FEW QUESTIONS
BUT PLEASE FEEL FREE TO ASK
FOLLOW UPS AND YOU KNOW I MAY
HAVE TO REFER TO YOU OTHER
RESOURCES OR PERHAPS ASK LEADERS
TO PINCH HIT BUT STARTING WITH 1
QUESTION THAT I GET ASKED ALL
THE TIME AND I HAVE A CANNED
ANSWER FOR, I APOLOGIZE BUT I
WILL TRY TO BUILD ON IT A LITTLE
BIT AND THE QUESTION IS WHEN
WILL THE T15 BE RENEWED?
THIS IS AN ACTIVE DISCUSSION
WITHIN THE PROGRAMS AND THERE'S
CERTAINLY AN AWARE OF THE
POSITIVE MOMENTUM IN THE T15 AND
VALUABLE LEGACY OF THE PROGRAM,
THAT SAID WE'RE ALSO ADAPTING TO
MANY CHANGES AT NIH THAT REQUIRE
US TO CLOSELY MAINTAIN STRATEGY
FOR THE TRAINING PROGRAM
SUPPORTED BY NLM.
SO 1 PARTICULARLY BIG CHANGE IS
THE LOCUS MOVING FROM NLM TO CSR
AND THAT HAPPENED EARLIER THIS
YEAR AND ANOTHER CRITICAL
QUESTION THAT NLM NEEDS TO
ANSWER IS HOW IS THE T15
DIFFERENT FROM THE NIH PARENT
T32?
NOT THE FIRST TIME THAT
QUESTION'S BEEN ASKED BUT HAVING
GOOD ANSWER SYSTEM GOOD PRACTICE
AND AS A MEMBER OF THE NIH,
TRAINING ADVISORY COUNCIL I'M
CERTAINLY MONITORING THESE
CHANGES AND THINKING CRITICALLY
OF THE PLACE THAT THE T15 HOLDS
AND NLM'S GRANTS PORTFOLIO AND
WHAT THAT COULD LOOK LIKE GOING
FORWARD.
SO TO KIND OF BUILD ON THIS
QUESTION A LITTLE BIT, AND KIND
OF ADD SOME, YOU KNOW, I'LL SHOW
YOU HOW WE'RE APPROACHING THIS
QUESTION, HOW WILL THE T15
PROGRAM BE EVALUATED INTO THE
CURRENT COHORT?
YOU KNOW YOUR THOUGHTS ON THIS
QUESTION?
BUT THE PLANNED APPROACH
INCLUDES BASIC ELEMENTS, THE
MOST IMPORTANT IS TRAINEE
DEVELOPMENT AND THIS IS WHERE WE
ANALYZE TRAINEE PROGRESSION
THROUGH PROGRAM MILESTONES.
WE TAKE CRITICAL EYE TO RESEARCH
PRODUCTIVITY, CAREER PLACEMENT
AND WHETHER THEY WIN SUBSEQUENT
RESEARCH GRANTS OF THE IT'S
WORTH MENTIONING THAT UNLIKE ARE
MANY OTHER NIH TRAINING
PROGRAMS, NLM T15 TRAINEES THAT
TAKE UP INDUSTRY POSITIONS OFTEN
CONTINUE TO DO ACADEMIC WORK IN
THESE ROLES, YOU KNOW IN
INCORRECTLY UTILIZE THE SKILLS
AND EXPERIENCE THAT THEY GOT
WHILE THEY WERE A T15 APPOINTEE.
YOU KNOW AND THEN, ALSO, THAT
RESEARCH AREAS, THE TRAINEES
WORK IN, OFTEN HAVE OTHER MAJOR
SUPPORT BEYOND THE NIH, SO THE
OLD ASSUMPTIONS ABOUT WHAT
CAREER SUCCESS LOOKS LIKE DON'T
NECESSARILY HOLD UP WELL FOR T15
TRAINEES.
AND THEN THE SECOND PIECE OF
THIS, IS LOOKING AT PROGRAM
SCIENTIFIC SCOPE, WHERE WE WILL
ASSESS CURRICULUM DEVELOPMENT
WITH RESPECT TO NIH STRATEGIC
PRIORITIES, AND EMERGING
SCIENTIFIC OPPORTUNITIES AND
ALSO LOOK CRITICALLY AT THE
PRESENCE OF ADEQUATE EXPERTISE
OF THESE PROGRAMS TO SUPPORT THE
CURRICULA.
WE CERTAINLY EXPECT THESE
PROGRAMS TO BE FORWARD LOOKING
AND SHOWING REALLY STRONG
ADAPTATION TO RAPIDLY EMERGING
TECHNOLOGIES AND YOU KNOW
RESPONDING TO STRATEGIC
SCIENTIFIC OPPORTUNITIES.
WITH THAT, HAPPY TO ANSWER ANY
QUESTIONS THAT YOU MIGHT HAVE.
>> THANK YOU CLAYTON.
I'LL ASK JIM SAMINO, AND
DR. LORE TO WEIGH IN WITH
QUESTIONS AND OPEN UP DISCUSSION
FURTHER WITH BOARD MEMBERS AS
WELL.
SO FIRST OF ALL I NEVER REALLY
UNDERSTOOD THE RELATIONSHIP
BETWEEN T15 AND T32.
IF THERE'S AN OPPORTUNITY TO
EXPAND THE PROGRAM BY ADDING 17
TO IT TO MAKE IT 32, THAT WOULD
BE GREAT BECAUSE THERE'S
CLEARLY, PART OF THE PROSPECT IS
THAT THERE'S A -- PROBLEM IS
THAT THERE'S A NEED FOR MORE
TRAINING AND THE TRAINING SITES
THAT ALREADY HAVE GRANTS
BASICALLY ARE EASILY ABLE TO
OUTCOMPETE THE NEW PLACES.
NEW PLACES HAVE TROUBLE GETTING
IN U.S. TRAINEES AND WE CAN'T
OFFER NEW TRAINEES WHAT WE HAVE
FOR EXPERIENCE FOR TRAINEESHIP,
MENTORSHIP.
AND YOU KNOW IT'S THE RICH GET
RICHER KIND OF A THING.
NOW THERE WERE 3 NEW PROGRAMS
THIS YEAR, BUT 2 OF THEM ARE
PROGRAMS THAT HAD BEEN PROGRAMS,
THAT LOST THEIR FUND NOTHING
PREVIOUS YEARS TO NEW PROGRAMS,
THOSE NEW YOU PROGRAMS WEREN'T
ABLE TO BE SUSTAINED.
SO YOU KNOW I THINK THERE'S --
IT'S WORTH THINK BEING WHETHER
THERE'S AN ALTERNATIVE
MECHANISM, MAYBE A SEPARATE
POPULATION OF PROGRAMS THAT
WOULDN'T BE COMPETING WITH THE
BIG PROGRAMS AND INSTEAD
COMPETING WITH EACH OTHER TO SEE
WHAT ARE THE NEW SEED PROGRAMS
THAT COULD BE STARTED.
AND I WOULD ALSO SAY IS THERE A
WAY TO WORK WITH OTHER
INSTITUTES IF THERE ARE ANY LEFT
TO YOU KNOW GET THEIR TRAINING
PROGRAMS TO HAVE COMPONENTS TO
SPONSOR INFORMATICS SEAT, YOU
KNOW?
FOR SIDE -- SO FOR WE HAVE T32S
IN ALL SORTS OF PLACES, IT WOULD
BE GREAT IF THEY SAID YOU KNOW
YOU NEED KNOW DEDICATED TO
INFORMATICS AND THAT MIGHT BE A
WAY TO HELP JUMP START SOME
PROGRAMS.
>> THANK YOU.
VERY USEFUL, YEAH, THE T15
ROUGHLY FOLLOWS THE POLICIES OF
THE T32 IN TERMS OF STRUCTURE
AND THE VARIOUS POLICIES,A ROUND
HOW INDIVIDUAL TRAINEES ARE
MANAGED AND APPOINTED AND
TERMINATED AND SO, FROM THAT
PERSPECTIVE SIMILARITIES SEEM TO
BE FEW.
A LOT OF THE WAY THE T15 HAS
BEEN STOOD UP BASED ON COHORTS
REGULARLY, KIND OF COMPETING IN
A POOL AGAINST EACH OTHER, EVERY
5 YEARS.
YOU KNOW THAT COMES WITH SOME
PROs, WE CAN PLAN, YOU KNOW
OUR BUDGET MANY YEARS IN ADVANCE
THINKING ABOUT THAT BUT THERE
ARE CERTAINLY SOME KINKS TO THAT
PROCESS THAT WE NEED TO BE
THINKING ABOUT ANYTHING INTO --
GOING INTO THE NEXT COUPLE OF
YEARS.
>> I ALSO AGREE WITH WHAT JIM
SAID, IT'S CLEARLY, CLEARLY
IMPACTFUL AND I'M WONDERING IF
THERE IS ANY INITIATIVE TO THINK
ABOUT THIS COLLABORATION THAT
JIM TALKED ABOUT IN TERMS OF
FINDING MORE INTERDISCIPLINARY
APPROACH ACROSS SCHOOLS AND
DISCIPLINE, I'M THINKING TO MAKE
THE T15 MORE IMPACTFUL BECAUSE
THE T32 PROGRAM SEEMS TO BE MORE
DEPENDING ON THE SCHOOLS AND
UNIVERSITIES, IT MAY BE VERY
PARTICULAR TO A CERTAIN AREA IF
THERE'S ANY THOUGHT ABOUT
DIVERSIFYING OR EXPANDING IT.
>> I MEAN THESE PROGRAMS ARE BY
NATURE INTERDISCIPLINARY BECAUSE
ESSENTIALLY WHAT THEY HAVE IN
COMMON IS INFORMATICS AND YOU
SEE JUST FROM THE PUBLICATIONS
THAT THOSE INFORMATIC SKILLS ARE
APPLIED VERY BROADLY ACROSS
SCIENCE AND I THINK THAT THAT'S
PART OF THE NARRATIVE THAT I'M
EVEN TRYING TO TELL ABOUT THE
T15 IS THAT IT'S AN NLM PROGRAM
THAT FLOATS ALL BOATS ACROSS
NIH.
AND IT IS THE INTERDISCIPLINARY
D15 THAT I FIND PARTICULARLY
COMPELLING.
I DON'T KNOW IF THAT ANSWERED
YOUR QUESTION.
>> YEAH, I WAS JUST LOOKING AND
THINKING ABOUT YOU THE NIH
INSTITUTES AND I DON'T SEE
NURSES AND NURSES DOES QUITE A
BIT OF INFORMATICS WORK, TOO, SO
I WAS CURIOUS LIKE WHERE ARE THE
NURSES IN THIS THING?
SO MAYBE BECAUSE YOU DIDN'T
PRESENT THE CHARACTERISTICS OF
THE TRAINEES, BUT IT WOULD BE
INTERESTING TO SEE WHAT THAT
COMPOSITION LOOKS LIKE BETWEEN
THE T32s AND THE T15?
>> SO WE DON'T HAVE T32s HERE
AT NLM, I WAS MERELY REFERENCING
THAT THE AS A DISCUSSION
HAPPENING ACROSS NIH ABOUT
THINKING CHRISICALLY ABOUT THE
PROGRAMS WE HAVE AND THEIR
SIMILARITIES AND DIFFERENCES IN
JUSTIFYING THEM, YOU KNOW ON
THAT BASIS.
>> THANK YOU.
>> SO YOU PRESENTED THE
DIFFERENT TRAINING SITES, BUT I
THINK 1 ARGUMENT THAT SORT OF
SHOWCASES THE IMPACT THAT THE
NLM HAS IS THAT A PARTICULAR
SITE ISN'T NECESSARILY CONFINED
TO 1 INSTITUTION SO WHEN I WAS
IN BOSTON THAT TRAINING SITE HAD
MULTIPLE HOSPITALS, BUT IT ALSO
REACHED OUT TO TUFTs MEDICAL
CENTER AT THAT TIME AND IT
WASN'T JUST HARVARD AND I JUST
WONDER IF THEREYA Y -- THERE'S A
WAY TO SHOW THAT WITH THE
INSTITUTIONS THAT IT'S NOT JUST
A LISTED INSTITUTION BUT TO
JIM'S POINT THAT THERE DOES NEED
TO BE A WAY TO START BRINGING IN
NEW INSTITUTIONS BUT THAT THOSE,
I THINK 18 IT'S NOT AS LIMITED
AS IT LOOKS.
>> YEAH, WE HAVE A COUPLE OF
EXAMPLES THAT HAVE NOT JUST 2 OR
3 INSTITUTE PARTNER INSTITUTIONS
BUT A DOZEN OR MORE, RIGHT?
AND I THINK THAT YOU KNOW IT'S
ALWAYS THE PREROGATIVE OF
APPLICANTS TO SUGGEST SUCH A
MODEL FOR THEIR T15 AND THAT
COULD BE 1 WAY OF SORT OF
EXPANDING THE REACH ACROSS
GEOGRAPHIC REACH BUT ANY KIND OF
CAPTURING DESIRE TO ENTER
DISCIPLINEARITY THAT PERHAPS
REQUIRES COLLABORATION OF
ADDITIONAL INSTITUTIONS.
IT'S ALWAYS BEEN THE PREROGATIVE
OF APPLICANTS TO PROPOSAL.
>> YES, IT'S THE PREROGATIVE OF
THE APPLICANTS BUT CAN NLM HAVE
INTENTS FOR APPLICATIONS TO
COLLABORATE ACROSS THE
INSTITUTIONS AND MORE
INSTITUTIONS.
>> IT'S A GOOD THOUGHT AND
DEFINITELY 1 WE WILL DISCUSS.
>> ARE THERE OTHER QUESTIONS FOR
CLAYTON?
>> OKAY, THANK YOU, THANK YOU
ALL.
>> THANK YOU SO MUCH.
>> SO ARE THERE ANY MORE
QUESTIONS GO GENERAL?
WE ARE A LITTLE AHEAD OF TIME
AND I SEE IF STEVE HAS ANY LAST
THOUGHTS FOR US OR ANY OF THE
BOARD MEMBERS HAVE ANY QUESTIONS
FOR STEVE OR THE NLM LEADERSHIP?
>> SEEING NO QUESTIONS, LOLA AND
EVERYONE, I WOULD LIKE TO THANK
YOU FOR A GREAT MEETING TODAY,
REALLY HELPFUL INSIGHTS, DIGS
CUSHIONS AND QUESTIONS, IT'S
BEEN REALLY GREAT TO STRENGTHEN
AND SECURE THE DIRECTION OF OUR
EXTRAMURAL PROGRAM AND SOME OF
THE STRATEGIC WORK THAT WE'LL BE
DOING JUST TO REMIND EVERYONE,
WE WILL HAVE A NLM STRATEGIC
PLANNING EXERCISE STARTING NEXT
YEAR, OR STARTING IN THE FALL OF
THIS YEAR, I THINK IT WILL BE
FISCAL 26, SO STAY TUNED FOR
THAT.
I THINK THERE WILL BE MORE
INFORMATION COMING AND UPDATE TO
FUTURE MEETINGS ON THAT PROCESS
AND I GUESS WITH THAT, IF THERE
ARE NO QUESTIONS, I JUST WANT TO
THANK EVERYONE AGAIN FOR A
PRODUCTIVE MEETING TODAY AND
ENJOY YOUR SUMMER AND WE WILL
RECONVENE AS A GROUP IN OCTOBER.
BYE-BYE.
THANK YOU VERY MUCH.
>> GREAT.
THANK YOU.
>> GOOD TO SEE YOU ALL.
>> ADJOURN THE MEETING.
BYE